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Summary 
The respiratory tract is exposed to a wide range of environmental constituents 
including potentially infective agents.  This thesis presents two series of papers 
concerning two atypical organisms and their sequelae or potential sequelae – 
Coxiella burnetii, which causes Q fever, and flagellated protozoa, which is 
associated with respiratory symptoms and asthma. 
The first series of papers examine a Q fever outbreak and its sequelae.  They 
describe one of the largest Q fever outbreaks in the UK and demonstrate the 
benefit of facsimile cascade in supporting case searching in such an outbreak.  
Chronic fatigue (Chalder Fatigue scores) and depression (PHQ-9 scores) were 
raised in post Q fever patients six years later (p<0.05 in both cases).  
Concordance regarding serological status across three international reference 
laboratories was as low as 35%, indicating a major problem with international 
standardisation in this area.  Unpublished supplementary clinical and serological 
findings are also presented to inform future outbreak investigation. 
The second series of papers examine the role of flagellated protozoa in 
respiratory disease.  Flagellated protozoa were shown to be present in a case 
series of inpatients.  In a subsequent community-based case control study, 
protozoa were present in 67% (20/30) of induced sputum samples taken from 
asthmatics and 31% (4/13) of samples from non-atopic controls (p=0.046).  In 
another study of inpatients, 67% of those who were on oral steroids had 
protozoa in their sputum, compared to 35% of those not on oral steroids.  In 
this study, 45% of smokers/ex-smokers had protozoa in their sputum compared 
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to 30% of non-smokers.  Unpublished data using molecular techniques to 
identify eukaryotes in sputum is also presented. 
The findings provide a basis for a RCT of antibiotics in patients with post Q fever 
chronic fatigue and a trial of anti-protozoal agents to eradicate flagellated 
protozoa in patients with asthma. 
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1 Introduction 
The human lung is in contact with more than 15,000 litres of air each day 
(Bartsch et al., 1982).  It has a surface area of around 50 m2 (Hasleton, 1972).  
This leads to extensive exposure to environmental constituents including 
potentially infective agents.  The air we breathe contains large quantities of dust 
and bacteria.  Each breath contains around 5,000 particles of dust (Bunnell, 
2002).  Most of this dust comes from around 2 billion tons of dust that is lifted 
into the earth‟s atmosphere each year.  This dust also contains bacteria and, on 
average, the dust in the earth‟s atmosphere contains 10,000 to 100,000 bacteria 
per gram of dust (Griffin et al., 2002).  The „respirable dust‟ fraction generally 
consists of particles smaller than 5µm (Choiniere and Munroe, 2001, World 
Health Organisation, 1999).  These minute particles are not visible to the naked 
eye and exposed individuals are generally unaware that they are inhaling dust 
particles of this size.  This extensive exposure to the environment means that 
the lungs are a common portal for infection by viruses, bacteria, fungi, protozoa 
and other infectious agents. 
A wide range of typical and atypical respiratory infections have been described.  
The term „atypical respiratory infection‟, or „atypical primary pneumonia‟, was 
first used in 1944 (Marmion, 1990) and has proved useful in describing 
respiratory infections that are caused by atypical organisms and which present 
with atypical symptoms.  Coxiella burnetii, the cause of Q fever, is one of these 
atypical respiratory pathogens (Saikku, 1997) and is a  focus within this thesis.  
The other focus in this thesis is the relationship between another atypical 
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respiratory tract organism (flagellated protozoa) and its relationship with 
respiratory disease. 
Historically, healthy lungs were believed to be sterile.  However, there is 
increasing evidence that microbiota are present even in healthy lungs (Rogers et 
al., 2005, Rogers et al., 2006).  This finding is particularly relevant to this thesis, 
which relates to the potential overlap between pathogenic and commensal 
protozoa and other microbiota in the respiratory tract.  A recent study using 
metagenomic culture independent genomic techniques has demonstrated 
increased levels of Proteobacteria, particularly Haemophilus, and a decreased 
level of Bacteroides, particularly Prevotella, in patients with COPD (Hilty et al., 
2010).  The study also found that microbial communities in asthmatic airways 
were disordered, with pathogenic Proteobacteria more frequently found in the 
bronchi of asthmatic patients than in controls. 
It is well recognised that commensal organisms can become pathogenic given 
the right circumstances, leading to sub-clinical or overt infection.  However, 
there is emerging evidence that microbiota may form part of a complex causal 
web that results in disease, for example, by their effects on the immune system, 
without becoming pathogenic in the classical sense.  The role of such organisms 
in respiratory disease is controversial, but is key to the proposal in this thesis 
that there is a link between atypical flagellated protozoa and respiratory disease. 
1.1 Aims and objectives 
This thesis presents two series of published papers relating to two atypical 
respiratory organisms.  The first series of papers examines Coxiella burnetii – 
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the cause of Q fever, its investigation and its sequelae.  This series of papers is 
based on the cohort exposed to a Q fever outbreak in Newport, Wales in 2002.  
The second series of papers examines the relationship between atypical 
flagellated respiratory protozoa and clinical and immunological characteristics 
associated with respiratory disease. 
In examining the Q fever outbreak and its sequelae, the objective of each of the 
papers in the series is to: 
 Describe the investigation of one of the largest Q fever outbreaks to have 
occurred in the UK 
 Assess the use of facsimile cascade in supporting case finding in such an 
outbreak 
 Assess the longer term sequelae in the exposed cohort, particularly in 
terms of chronic fatigue and depression 
 Assess the consistency of three international reference laboratories in 
diagnosing chronic Q fever 
In examining flagellated protozoa and their potential sequelae, the objective of 
each of the papers in the series is to: 
 Assess whether flagellated protozoa were present in respiratory inpatients 
in the UK 
 Assess the relationship between asthma and flagellated protozoa in the 
community 
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 Assess the relationship between clinical and immunological characteristics 
and the presence of protozoa in sputum smears in respiratory inpatients 
1.2 Structure of this thesis 
The commentary in this thesis is provided in two sections.  In each section, the 
series of papers is treated under the following headings: 
1. The wider research context 
2. Original contribution made 
3. Methodological considerations 
4. Discussion of findings 
An overarching concluding chapter then brings together the findings of the 
papers and considers potential lines for further research. 
In line with Cardiff University‟s Senate Regulations for the Award of the Degree 
of PhD (by Published Works), information on the personal contribution to the 
papers is provided in Appendix 1. 
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2 A Q fever outbreak and its sequelae 
Q fever was first described by Derrick and Burnett in Australia following the first 
recognised outbreak in 1935 (Cooke, 2008, Burnett and Freeman, 1937). The 
underlying aetiological organism (C. burnetii) has subsequently been shown to 
occur in almost every country in the world (Tissot-Dupont and Raoult, 2008).  
The commonest mode of infection with C. burnetii is inhalation of organisms 
from an environmental source.  The organism can survive in a dormant form for 
many years and has an infective dose as low as one organism (Williams, 1991).  
Very large quantities (up to 109 organisms per gram) can occasionally be found 
in infected placenta (Welsh et al., 1953). 
2.1 The wider research context 
Given its relatively small population, a surprising number of outbreaks of Q fever 
have been documented in Wales (Anon., 1956, Salmon et al., 1982).  Rural 
inhabitants are more exposed to C. burnetii and the number of previous 
outbreaks in Wales may be related to its rural geography and extensive livestock 
farming industry.  In one sero-prevalence study, farm workers had a sero-
prevalence of 27.2% compared to police and emergency workers who had a 
sero-prevalence of 10.9% (Thomas et al., 1995).  
2.1.1 The initial Q fever outbreak 
The Q fever outbreak reported by the author (van Woerden et al., 2004, 
ENCLOSED PAPER) occurred in a factory in Newport, Wales.  In view of the 
previous rural outbreaks in Wales, the initial investigation focused on the rural 
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hinterland as a possible source of infection.  However, the hypothesis that was 
finally settled upon and presented in the attached research paper was that the 
outbreak had been caused by infected material present in straw board, which 
was present within the factory itself.  The renovation work on straw board in the 
factory is shown in Figure 1. 
 
FIGURE 1: RENOVATION WORK INVOLVING THE STRAW BOARD CEILING 
(PHOTOGRAPH COURTESY OF DR R SMITH) 
The outbreak presented was one of the largest to be described in the UK.  The 
only other UK outbreak of comparable size occurred in the West Midlands in 
1989 (Hawker et al., 1998).  The exposed cohorts have been followed up in both 
outbreaks.  Both follow up studies have demonstrated that chronic fatigue is 
present 6-10 years later in a proportion of those affected by Q fever (Wildman et 
al., 2002, van Woerden et al., 2011a). 
A number of subsequent large outbreaks of Q fever have occurred in Europe.  In 
particular, there has been an on-going Q fever outbreak in the Netherlands since 
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2007 (van der Hoek et al., 2010).  A large outbreak has also been reported in 
Scotland (Wilson et al., 2010b). 
2.1.2 The use of facsimile cascade in case finding during a Q fever 
outbreak 
The outbreak of Q fever provided an opportunity to evaluate the effectiveness of 
facsimile cascade in the context of a disease outbreak (van Woerden et al., 
2007, ENCLOSED PAPER).  Rapid identification of as many of the cases involved 
in an outbreak as is possible is essential in aiding rapid identification of an 
outbreak‟s source and prevention of further cases.  Although email is 
increasingly replacing facsimile as a means of rapid communication, many 
primary care physicians are overloaded with emails (Dabbish and Kraut, 2006, 
van der Kam et al., 2000) and communication by facsimile may be given a 
higher priority.  The study provided some evidence that facsimile cascade was 
effective in triggering a response from GPs.  One of the practical lessons learned 
from this case study was the fact that effective facsimile cascade is dependent 
upon contact details held in a central database being up to date.  Health 
protection departments should ensure that their facsimile cascade contact lists 
are cleaned and updated on a regular basis. 
2.1.3 Follow up at six years 
Q fever can lead to long-term sequelae including endocarditis, as happened to 
one patient in this outbreak (Healy et al., 2006), and to chronic fatigue (Ayres et 
al., 1996, Hatchette et al., 2003, Wildman et al., 2002).  For this reason, a 
follow up study was planned by the author at the time of the outbreak and 
subsequently undertaken six years later (van Woerden et al., 2011a, ENCLOSED 
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PAPER).  This paper reports a nested case control study utilising the initial cohort 
of factory workers exposed to Q fever in 2002.  The paper demonstrated that 
chronic fatigue, measured by the Chalder Fatigue questionnaire, was more 
prevalent in those who were defined as having acute Q fever six years 
previously.  An analysis was also undertaken using the questionnaires that were 
completed and the blood samples that were taken at the time of the six-year 
follow-up in 2008.  The results demonstrated a relationship between C. burnetii 
Phase 2 IgG and depression using PHQ-9 scores.  As far as the author is aware, 
an association between raised C. burnetii Phase 2 IgG titres and depression has 
not previously been described. 
2.1.4 International comparison of laboratory results 
A subsequent paper was also based on the six-year follow-up of the cohort of 
factory workers exposed to Q fever.  In this paper microimmunofluorescent titres 
from cases and non-cases were submitted to three international reference 
laboratories in France, Australia and the UK (Healy et al., 2011, ENCLOSED 
PAPER).  The study demonstrated that the results of Q fever micro-
immunofluorescence varied according to the centre in which the samples were 
analysed.  Concordance between laboratories using the same set of patient 
blood samples was 35% (18/52) when the French results were compared to the 
UK results; 42% (22/52) when the French results were compared to the 
Australian results; and 71% (37/52) when the Australian results were compared 
to the UK results. 
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2.2 Original contribution made 
The outbreak report was ground breaking in that it suggested that C. burnetii 
might have been present in the straw board for 60 years before causing the 
outbreak.  Although spores from other species, such as anthrax, have been 
shown to survive for many decades, this is the first time that C. burnetii has 
been postulated to have lain dormant for so long.  The organism has been shown 
to survive in dried form for at least eight years (Philip, 1948).  It is also very 
resilient and can withstand pressures of up to 20,000 lb/in2, elevated 
temperatures, desiccation, osmotic shock, UV light, and chemical disinfectants 
(McCaul and Williams, 1981). 
Although straw has been implicated in other outbreaks (Jorm et al., 1990), these 
have been in an outdoor context, whereas the straw in this outbreak was within 
internal straw-board walls.  This is the first study to postulate straw board as the 
cause of a Q fever outbreak.  The study demonstrates the need for caution in the 
increasing trend to use natural materials such as straw in house building, as 
straw can potentially provide a reservoir of infective material. 
The study of facsimile cascade was novel in addressing the effectiveness of the 
technique in the context of a disease outbreak (van Woerden et al., 2007).  This 
question had not been previously considered in the context of outbreak 
management.  The study presented found that, compared to the previous year, 
the number of samples submitted for Q fever testing rose significantly in the 
period just after the facsimiles were sent to GP practices (Paired Wilcoxon signed 
rank test p<0.001). 
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The follow up study had the advantage that a cohort of individuals could be 
identified all of whom had been exposed to a point source of C. burnetii.  The 
benefit of this design was that all of the individuals in the follow up cohort who 
had evidence of previous exposure to C. burnetii would probably have contracted 
the disease at around the same time.  This is because the background rate of 
infection with C. burnetii is very low.  Given the size of the cohort, and 
considering the six-year time frame, only one individual would be expected to 
have developed detectable antibodies to C. burnetii arising from the background 
rate of infection in the community (based on the prevalence in Thomas et al., 
1995).  We can reasonably conclude that almost all of the cases in the cohort 
with chronic fatigue and serological evidence of exposure to Q fever were 
infected six years previously in the 2002 outbreak and not at a later date.  In 
other words, this cohort study can be used to assess whether there is a temporal 
relationship between acute infection with Q fever and subsequent sequelae.  The 
study published by the author  (van Woerden et al., 2011a) demonstrated that 
when Chalder Fatigue scores for fatigue were dichotomised as „low‟ (0-3) and 
„high‟ (4-11) the „high‟ fatigue scores were significantly more common in the 
cases compared to non-cases (Fisher‟s Exact Test p=0.047). 
The follow up study has also provided previously unreported evidence for an 
association between raised Q fever serology and depression.  An analysis based 
on the follow-up data from 2008 indicated that when depression scores (PHQ-9 
scale) were dichotomised to above and below the median, raised depression 
scores were more common in those patients with raised Phase 2 IgG to C. 
burnetii (Mann-Whitney U=173.0; p=0.049).  The mean rank in 23 individuals 
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with a „low depression score‟ (0-3) was 19.52, whereas the mean rank in 22 
individuals with a „high depression score‟ (4-9) was 26.64. 
The study has provided further evidence that Q fever has significant long-term 
sequelae and raises the question as to whether the organism is still present in 
the affected individuals (Devanur and Kerr, 2006) and whether trials of 
antibiotics might help patients with post Q fever chronic fatigue.  The author 
believes that there is a case for a RCT to evaluate this. 
The paper comparing serological results from three international reference 
laboratories (Healy et al., 2006) tackled a problem that has been suspected for 
some time but had not been addressed directly before.  The only previous 
research in this area compared the results from a single individual whose blood 
was tested by a commercial laboratory and by reference laboratories in France 
and the USA (Ake et al., 2010). 
The results are concerning.  Concordance in the interpretation of micro-
immunofluorescence results between different pairs of laboratories was as low as 
35%.  Differences were most marked in relation to the definition of chronic cases 
of Q fever.  Comparative serological analysis revealed no „chronic‟ serological 
profiles when the set of samples was tested in either France or Australia but 10 
such serological profiles when the same samples were tested in the UK reference 
laboratory.  This issue is of concern as the three laboratories in question are 
among the most important reference laboratories in the world for this disease.  
This work has been cited by subsequent authors who also recognise the 
importance of this problem (Sunder et al., 2011, Kampschreur et al., 2012). 
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2.3 Methodological considerations 
Several of the papers presented arise out of an initial disease outbreak.  
Although outbreaks can be tightly defined as, “the occurrence of more cases of 
disease than expected in a given area or among a specific group of people over a 
particular period of time” (Centers for Disease Control and Prevention, 2011), 
the methodology underpinning the investigation of an outbreak does not have 
the repeatability of a scientific experiment (Gregg, 2008).  However, standard 
study designs can be incorporated.  In this outbreak, a „cohort‟ and nested-case 
control study design was used.  Although the initial Q fever investigation 
demonstrated a clear epidemic curve, no microbiological confirmation of C. 
burnetii in materials take from the site was achieved.  Microbiological 
confirmation would have significantly strengthened the straw board hypothesis, 
which has to remain tentative in its absence (Reingold, 1998).  
The facsimile study could also have been strengthened in a number of ways, for 
example, by a telephone survey of GPs to ascertain whether the facsimiles had 
been read by GPs and to determine the extent to which the facsimiles had 
influenced behaviour in consultations.  Further work could also have been 
undertaken to determine the number of patients attending GP surgeries that met 
the case definition and the proportion for whom Q fever serology was requested. 
The main weakness of the six-year follow up demonstrating chronic fatigue was 
the small size of the control group.  This was because the response rate in 
controls was low.  Control participants who did attend may not have been 
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representative of the factory workers as a whole.  A second control group from 
another occupational setting would also have strengthened the study. 
The comparison of laboratory results from three reference laboratories assessed 
the reproducibility of a diagnostic test (Banoo et al., 2006).  However, the 
sample size in this study was small with only 37 discordant results.  The 
inclusion of a larger number of samples from a range of outbreaks across the 
world would have strengthened the study, as there is geographical variation in 
the antigens expressed by different strains of C. burnetii and differences in the 
resultant immunological response. 
2.4 Discussion of findings 
This Q fever outbreak has been referenced in reports of subsequent outbreaks 
(Morovic et al., 2008, Harzing, 2007, Wilson et al., 2010a, Amitai et al., 2010).  
The paper on facsimile cascade has also been quoted as being one of the better 
studies in a systematic review of public health emergency preparedness and 
response (Revere et al., 2011). 
The paper comparing serological results from three international reference 
laboratories, and demonstrating the differences obtained on the same set of 
samples from these laboratories has generated some discussion (Kampschreur 
et al., 2012, Sunder et al., 2011).  The discordance has implications for the 
definition of chronic Q fever and for the interpretation of serology results 
obtained in the context of trials of different treatment regimens.  There is an 
urgent need for the development of an agreed set of international standard 
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materials for C. burnetii, international agreement on laboratory procedures, and 
a system of international cross checking of a subset of samples. 
2.5 Unpublished Q fever related findings 
Some additional findings associated with the series of Q fever papers are 
presented below. 
2.5.1 Unpublished findings related to symptoms reported in the Q 
fever outbreak 
One of the challenges in outbreak investigation is distinguishing common 
respiratory tract infections that are present in any population at any given time 
from acute Q fever, based solely on clinical symptoms.  The analysis below 
compared the symptoms of individuals with acute Q fever and individuals 
without Q fever, based on serological criteria.  The definition of acute Q fever in 
this context was „any phase 2 IgM titre, or a fourfold rise in complement fixation 
tests (CFT)‟ (van Woerden et al., 2004).  The comparative group without Q fever 
was defined in this context as „individuals who were in the cohort exposed to Q 
fever and who reported that they were unwell when completing the 
questionnaire during the initial outbreak investigation, but who had no Q fever 
antibody titre by micro-immunofluorescence or CFT, in blood samples taken at 
that time‟.  It is possible to speculate that most of these „control‟ patients had 
incidental viral upper respiratory tract infections at the time of the outbreak.  A 
comparison between those with acute Q fever and other inter-current illnesses is 
shown in Table 1 below. 
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TABLE 1: ODDS RATIOS FOR THE PRESENCE OF SYMPTOMS IN 
SEROLOGICALLY POSITIVE AND NEGATIVE CASES SAMPLED AT THE 
TIME OF THE OUTBREAK IN 2002 
 Acute Q 
Fever 
(symptomatic 
and 
serologically 
positive) 
Not Q fever 
(symptomatic but 
serologically 
negative) 
Odds ratio p value 
(Fisher‟s 
Exact test) 
Fever 42 8 
  No fever 15 11 3.85 0.024 
Sweats 54 18 
  No sweats 7 8 3.63 0.031 
Headache 52 18 
  No 
headache 7 9 3.714 0.034 
Cough 26 17 
  No cough 29 8 0.422 0.097 
Shortness 
of breath 26 17 
  No 
Shortness 
of breath 29 8 0.422 0.097 
Joint pain 47 13 
  No joint 
pain 8 11 4.971 0.004 
Chest pain 21 7 
  No chest 
pain 32 15 1.406 0.606 
Weight loss 27 2   
No weight 
loss 28 27 8.196 0.003 
 
Amongst symptomatic individuals, fever, sweats, headache, joint pain and 
weight loss were significantly associated with a serological diagnosis of acute Q 
fever (p<0.05).  Cough was very common in both groups and therefore did not 
help distinguish individuals with Q fever.  The questionnaire administered at the 
time of the outbreak did not contain questions on myalgia or fatigue, which was 
asked about at subsequent outpatient appointments.  The addition of these two 
questions would be useful in future outbreaks. 
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Testing for viral infection would have been helpful in more definitively excluding 
„possible‟ cases of Q fever, as acute Q fever was only diagnosed in some cases 
by paired sera demonstrating a rise in CFT titre.  Q fever testing and virology 
testing are normally undertaken in the same laboratory, which would make 
simultaneous testing feasible.  The case for simultaneously testing for a range of 
common respiratory viruses in Q fever outbreaks is strengthened by the fact that 
the price for testing for common respiratory viruses is now relatively low. 
In order to assess whether symptoms predicted serological status at the time of 
the outbreak a binary logistic regression was explored using „enter‟, „forward‟ 
and „backward‟ stepwise (likelihood ratio) approaches, in SPSS version 20.  The 
statistically significant associations identified above - fever, sweats, headache, 
joint pain and weight loss were entered into the model.  „Fever‟ was dropped due 
to its association with „sweats‟.  The result of the baseline model which included 
all the variables i.e. weight loss, headache, joint pain and sweats, is shown in 
Tables 2 and 3. 
TABLE 2: CLASSIFICATION TABLE FOR LOGISTIC REGRESSION 
ANALYSIS 
 
Observed  
Status Percentage 
Correct Serology 
Negative but 
symptoms 
Acute Q fever 
Step 1 
Status 
Serology Negative but 
symptoms 
8 7 53.3 
Acute Q fever 4 45 91.8 
Overall Percentage   82.8 
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TABLE 3: VARIABLES INCLUDED IN THE COMPOSITE MODEL 
PREDICTING SEROLOGICALLY NEGATIVE AS OPPOSED TO 
SEROLOGICALLY POSITIVE PATIENTS 
 
B S.E. Wald df Sig. Exp(B) 
Step 1 
Weight loss -2.230 1.154 3.735 1 .053 .108 
Headache -1.622 1.046 2.407 1 .121 .197 
Joint pain -.701 .924 .575 1 .448 .496 
Sweats -.373 .876 .181 1 .671 .689 
Constant 3.820 1.128 11.460 1 .001 45.586 
 
This model correctly classified 82.8% of cases in the dataset as serologically 
positive or negative.  Other models were generated but none of these predicted 
a greater percentage of the cases in the dataset.  A forward stepwise (likelihood 
ratio) model reduced to two factors „weight loss‟ and „headache‟, predicted 
82.8% of cases, and a backward stepwise (likelihood ratio) model reduced to 
„joint pain‟ and „sweats‟, also predicted 82.8% of cases.  The instability of the 
variables included in forward and backward stepwise models may be due to 
missing data and the co-linearity of the variables. 
The model is open to a number of criticisms.  There was variation in the time 
between the onset of symptoms and the time that blood tests were taken.  The 
sample size was relatively small and the model was not tested against a 
separate dataset.  However, a more fully tested model could prove clinically 
useful in distinguishing patients with acute Q fever in the context of an acute 
outbreak. 
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2.5.2 Unpublished serological findings related to the Q fever 
outbreak 
Tests for Q fever are problematic as there is wide inter-individual variation in 
antibody response and variation in the antigens expressed by different strains of 
Q fever (Porter et al., 2011).  CFT is the most widely available test but is the 
least sensitive and often depends on detecting a rise in titre in paired sera (Peter 
et al., 1985).  There is no international consensus on the cut off threshold for a 
positive Q fever test result for tests using ELISA and immunofluorescence 
(Dupont et al., 1994). 
The interpretation of serological tests for Q fever is complex as different 
individuals may be pre-symptomatic, or at different phases in their immune 
response when blood is taken.  One patient in this outbreak had positive 
serology on a blood sample taken the day before he became symptomatic.  To 
address this issue, acute Q fever was defined in this outbreak using a composite 
endpoint. 
Both CFT and IF tests can miss cases, as is demonstrated in Table 4 below, 
where the relationship between Phase 2 IgM and CFT tests is shown.  In the 
analysis presented, the composite definition of acute Q fever was “micro-
immunofluorescence (IF) Phase 2 IgM greater than or equal to 80, or a fourfold 
rise in CFT in paired samples, or a single CFT result greater than or equal to 64”.   
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TABLE 4: COMPARISON OF INITIAL CFT AND PHASE 2 IgM SEROLOGY, 
AGAINST A COMPOSITE CASE DEFINITION OF ACUTE Q FEVER, FOR 106 
INDIVIDUALS 
 CFT (1st sample) 
Phase 2 IgM (1st sample) <8 8 16 32 64 128 256 512 >512 Total 
Negative 2 1        3 
80 1 1        2 
160 5 3  1      9 
320 1  1 2      4 
640 2 1 7 4 2 1    17 
1280 0   1  2  1  4 
>1280 5 1 4 13 13 16 13 1 1 67 
Total 16 7 12 21 15 19 13 2 1 106 
 
A range of factors contributed to the inclusion of different subsets of cases in the 
above table.  In the three cases shown in blue, the initial blood samples would 
not have led to a diagnosis of acute Q fever by either CFT or IgM.  These three 
cases were subsequently diagnosed based on paired sera.  The 11 cases in red, 
bold and italic font were included on the basis of raised Phase 2 IgG ≥320.  If 
the composite definitions of Q fever is accepted as a „gold standard‟, a single 
blood test for Phase 2 IgM would have identified 103/106 cases, a sensitivity of 
97.2%.  In contrast, using the same composite definition as the gold standard, 
initial CFT testing would only have identified 50/106 cases, a sensitivity of only 
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47.2% As a result, the cases shown in red would not have received a diagnosis 
of acute Q fever based on single CFT test.  This fact is widely recognised by 
laboratory staff, and CFT laboratory reports recommend that a second paired 
sample is taken.  However, the importance of this may be underestimated by 
clinical staff and it can be difficult to get a second sample in clinical practice. 
CFT is quoted in the literature as detecting around 65% of cases during the 
second week after symptom onset and 90% of cases by the fourth week (Porter 
et al., 2011).  The figure in this study was lower, as in many cases bloods were 
taken before the second week of infection.  The poor sensitivity of CFT is likely 
to be a problem in many Q fever outbreak investigations. 
The data in Table 4 suggests that a policy of screening for atypical pneumonia 
using CFT would completely miss the 23/106 (21.7%) of cases with a CFT of 8 or 
less.  Subject to cost constraints, there is therefore a case for using 
immunofluorescence tests routinely as part of screening for atypical pneumonia, 
or where a diagnosis of Q fever is being considered. 
2.5.3  Unpublished findings - 18 month follow up 
The cohort of patients with acute Q fever was followed up at a routine 
microbiology outpatient clinic for over five years by Dr M Llewellyn and Dr B 
Healy to identify any patients who developed long-term complications.  The 
author designed follow up forms that were used in the outpatient clinics to 
capture relevant symptoms and serological results.  Some of the collated 
findings are presented below. 
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The duration of symptoms for 60 acute cases of Q fever followed up over the 
subsequent 18 months is presented in Table 5.  Some of the patients with acute 
Q fever had symptoms that lasted for more than one year. 
TABLE 5: DURATION OF SYMPTOMS AS REPORTED AT OUTPATIENT 
CLINICS FOR 60 SYMPTOMATIC CASES OF ACUTE Q FEVER FOLLOWED 
UP OVER 18 MONTHS 
Duration 
(days) 
Fever 
(%) 
Sweats 
(%) 
Headaches 
(%) 
Cough 
(%) 
SOB 
(%) 
Joint 
pain(%) 
Chest 
pain(%) 
Fatigue 
(%) 
Lethargy 
(%) 
Myalgia 
(%) 
Back 
pain(%) 
Diarrhea 
(%) 
1-7 64.7 60.8 66.7 52.5 51.7 53.3 33.3 29.4 29.4 55.6 50.0 72.7 
8-14 25.5 25.5 22.2 26.2 20.0 20.0 33.3 17.6 17.6 19.4 11.5 27.3 
15-21 7.8 5.9 8.3 9.8 15.0 13.3 19.0 3.9 3.9 11.1 15.4 0.0 
22-28 2.0 3.9 2.8 3.3 6.7 3.3 4.8 3.9 3.9 0.0 7.7 0.0 
29-56 0.0 0.0 0.0 3.3 0.0 0.0 0.0 3.9 3.9 0.0 0.0 0.0 
57-182 0.0 3.9 0.0 1.6 0.0 0.0 4.8 11.8 7.8 2.8 3.8 0.0 
183-365 0.0 0.0 0.0 1.6 5.0 3.3 4.8 3.9 5.9 5.6 0.0 0.0 
365+ 0.0 0.0 0.0 1.6 1.7 6.7 0.0 25.5 27.5 5.6 11.5 0.0 
 
As expected, most symptoms such as diarrhea, headache, fever and sweats 
were short lived.  Other symptoms were more persistent.  In particular, lethargy 
and fatigue were present for more than one year in 25.5% of patients.  Some of 
the persistent symptoms may represent other coincidental but common 
pathologies.  Cough may represent asthma or other common respiratory 
disorders, and back pain may reflect normal levels of pathology in that 
occupational group.  However, persistent myalgia (5.6% for more than one year) 
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and joint pain (6.7% for more than one year) may represent long-term 
morbidity associated with the outbreak. 
2.5.4 Unpublished findings - five year follow up 
The development of Phase 1 antibodies is associated with the risk of developing 
chronic Q fever and is therefore appropriate to monitor as part of the follow up 
of patients with Q fever.  Among the 106 individuals initially identified as having 
acute Q fever in this outbreak, 97 had a follow up blood test for phase 1 IgG 
antibodies at some point over the subsequent five years.  Phase 1 IgG developed 
in 63.9% (62/97) of these patients.  Phase 1 IgG titres ranged from 160 to 
10,240.  In almost all cases, raised titres occurred in the first year, if they 
occurred at all.  On this basis, a one-year period of follow up could be 
recommended for all cases of acute Q fever with longer follow up for those with 
raised Phase 1 antibodies. 
It has been suggested that Phase 1 IgG ≥ 800 has a 100% sensitivity for 
detecting chronic Q fever (Dupont et al., 1994).  This threshold is also a major 
criteria for the diagnosis of infective endocarditis in the context of Q fever 
(Fournier et al., 1996).  In this cohort, eight patients met this criteria but only 
one has developed endocarditis so far.  Figure 2 provides information on the 
change in titres over five years. 
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FIGURE 2: CHANGES IN PHASE 1 IgG IN EIGHT PATIENTS, WITH AN IgG 
OF ≥ 800 AT SOME POINT, OVER FIVE YEARS OF FOLLOW UP (GRAPH 
COURTESY OF DR B HEALY) 
In most cases, there is a rise in titre in the first 12 months followed by a fall in 
titre.  However, in a few cases a second peak can be observed.  Ongoing 
surveillance of these cases is being undertaken and it is possible that some of 
the other cases will develop endocarditis in the future.  The findings of this study 
would support the recommendation that patients with an IgG of ≥ 800 at one 
year should be provided with long-term follow up. 
2.5.5 Unpublished findings - six year follow up and severity of 
fatigue 
The follow up of the cohort of individuals exposed to Q fever six years later 
focused on the sequelae of chronic fatigue.  Information was collected at a single 
clinic held by the author and Dr B Healy.  The published paper (van Woerden et 
al., 2011a) does not provide information on the severity of the fatigue 
experienced by participants.  Additional information on this is shown in Table 6 
below. 
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TABLE 6: RELATIONSHIP BETWEEN SEVERITY AND DURATION OF 
FATIGUE, IN THE YEAR PRECEDING THE SIX YEAR FOLLOW UP, FOR 36 
PATIENTS WITH PREVIOUS ACUTE Q FEVER 
Question 
What percent of the time do you feel tired? 
Number 
of cases 25% 50% 75% 100% 
If you are tired 
at the moment, 
how long has 
this lasted? 
< 1 week 
4 2 0 0 6 
  < 3 
months 
2 4 0 0 6 
  3 - 6 
months 
2 1 1 0 4 
  >= 6 
months 
2 9 2 7 20 
Number of cases 10 16 3 7 36 
 
Chronic fatigue is normally defined as fatigue for six months or more (Devanur 
and Kerr, 2006).  In this study, among those who had experienced chronic 
fatigue for six months or more, 90% (18/20) had been tired at least 50% of the 
time indicating that these patients were severely disabled by their post Q fever 
Chronic Fatigue. 
2.5.6 Unpublished findings - six year follow up and smoking 
 Information gathered at the six-year follow up was also used to examine the 
relationship between serological abnormalities and smoking. For this analysis, 
serological status was assigned to each individual based on the rules provided by 
Dupont et al. (1994), as shown in Table 7 below. 
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TABLE 7: DEFINITION OF STATUS USING SEROLOGICAL CRITERIA 
Status Definition 
Acute Phase 1 IgM ≥ 50 
Past Phase 2 IgG detected and Phase 1 IgG <800 
Negative No antibody detected 
Chronic Phase 1 IgG ≥ 800 or Phase 1 IgA≥25 
Borderline Chronic Phase 1 IgG ≥ 400 and < 800 
 
The results of 45 cases are presented in Table 8.  The 15 Borderline 
Chronic/Chronic cases are compared to the 30 cases with serological evidence of 
„past infection‟ or „no previous infection‟, based on their serological status. 
TABLE 8: RELATIONSHIP BETWEEN SEROLOGICAL RESULTS MEASURED 
IN THE UK REFERENCE LABORATORY AND SMOKING STATUS AT THE 
SIX-YEAR FOLLOW-UP CLINIC 
 
12 3 15 
12 18 30 
24 21 45 
Borderline 
Chronic/Chronic 
Negative/Past 
British 
Results 
Total 
Current/ 
Ex-smoker Never smoker 
Smoking status 
Total 
 
Smoking is associated with borderline chronic/chronic serological status (Odds 
ratio 6.0; p=0.014, Fisher‟s Exact Test).  As in many diseases, smoking seems 
to increase the probability of developing a more chronic serological pattern 
(Morroy et al., 2012).  Although this analysis does not provide unequivocal 
epidemiological evidence, it would be worth pointing out to patients who have 
acute Q fever that stopping smoking might reduce the risk of developing long 
term sequelae. 
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2.6 Summary of Q fever work 
The main strength of the Q fever work presented above is that it follows a cohort 
of individuals over six years, starting with one of the largest outbreaks to date in 
the UK, and examines the sequelae in that cohort.  The investigation of this 
cohort was also used opportunistically to investigate a number of issues such as 
the use of facsimile cascade and the congruence of international reference 
laboratories. 
The unpublished work on Q fever highlighted the weaknesses of single sample 
CFT tests, demonstrated the severity of chronic fatigue in some patients six 
years later, highlighted the association between smoking and chronic Q fever 
symptoms, and provided a regression model that with further development could 
be used to help clinically distinguish Q fever from other illnesses.  This might aid 
more rapid epidemiological analysis in future outbreaks and accelerate the 
pinpointing of the source of an outbreak. 
Follow up to the six-year stage has identified the value of follow up for all 
patients for one year and the long-term follow up of patients who have raised 
serology suggestive of chronic Q fever.  The follow up results may be suitable for 
publication in due course. 
A number of patients have developed chronic fatigue and depression.  Thought 
needs to be given to undertaking a trial of antibiotics in these patients.  If such a 
trial were well designed, it would clearly be publishable. 
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The relationship between smoking and chronic/borderline chronic serology 
merits wider recognition, and should clearly be raised with any patients who 
develop acute Q fever as stopping smoking might reduce the risk of sequelae. 
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3 Flagellated respiratory protozoa and their association 
with respiratory disease 
Prior to the author‟s involvement, two small studies had been undertaken in 
Spain examining the relationship between unidentified flagellated protozoa and 
respiratory disease.  The Spanish studies had demonstrated that protozoa were 
often present in the sputum of individuals with respiratory disease (Ribas and 
Mosquera, 1998) and in individuals who were immuno-compromised (Ribas et 
al., 2005).  The relationship between these unidentified protozoa and respiratory 
disease has received little attention by research groups elsewhere in the world.  
The research presented in this thesis is, therefore, contentious and requires 
further international validation. 
3.1 The wider research context 
The first of the Spanish studies referred to above identified protozoa in 15/19 
patients with asthma, as opposed to 9/78 patients with other respiratory 
diseases, mostly COPD  (Ribas and Mosquera, 1998).  This was followed up by a 
second study that examined sputum from immuno-compromised patients, 
primarily patients with HIV infection, who had a productive cough.  This case 
series found that 72/106 patients had protozoal forms present in sputum (Ribas 
et al., 2005). 
3.1.1 A case series 
To examine whether these findings could be replicated in the UK, the author 
undertook a small pilot study in Cardiff using spontaneously produced sputum 
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samples from hospital inpatients (van Woerden et al., 2010, ENCLOSED PAPER).  
At that time, it was unclear whether the presence of flagellated protozoa in 
sputum was an isolated phenomenon restricted to Spain (or perhaps to climates 
with high temperatures), or was a wider phenomenon that would also be present 
in more temperate climates such as in the UK.  The case series demonstrating 
that protozoa were present in a significant proportion (50%) of inpatients in 
Cardiff indicated that the observation of protozoa in sputum was an international 
phenomenon.  An unpublished case has been identified (email correspondence, 
Richard Kibbee, Environmental Microbiologist, Centre for Research on 
Environmental Microbiology, University of Ottawa, Canada).  The photograph of 
the protozoa identified is shown in Figure 3 below. 
 
FIGURE 3: PHOTOGRAPH TAKEN 27 FEBRUARY 2009, DEPICTING 
PRESUMPTIVE PROTOZOAL BODY; ABSOLUTE MAGNIFICATION ~1000X 
(RICHARD KIBBEE) 
 
Another unpublished case was identified by correspondence with Saskia 
Grobben, Applied Plant Research Unit, Lelystad, Netherlands.  In this case, 
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protozoa were identified in sputum on three consecutive days.  The photographs 
obtained are shown below. 
    
FIGURE 4: PHOTOGRAPHS OF PUTATIVE PROTOZOA IN SPUTUM 
(SASKIA GROBBEN, 29 DECEMBER 2011) 
The photographs are similar in appearance to those taken by Spanish 
colleagues, with flagella covering at least a proportion of the circumference of 
the organism seen under light microscopy.  Both samples were related to an 
acute exacerbation of respiratory symptoms against a background of asthma. 
3.1.2 Case control study in the community 
A case control study was undertaken using induced sputum comparing the 
prevalence of protozoa in the sputum of patients in the community with asthma 
and in non-atopic controls (van Woerden et al., 2011b, ENCLOSED PAPER).  In 
this study 66.7% (20/30) of asthmatics and 30.8% (4/13) of non-atopic controls 
had protozoa in their sputum (p=0.046).This study provided evidence that 
protozoa were not only found in the sputum of patients in hospital, but were 
common in patients with asthma in the community. 
31 
 
3.1.3 Case comparison study in hospital patients 
In another case comparison study, the author and colleagues demonstrated that 
there was an association between the presence of monocytes or small 
macrophages and protozoa in sputum samples (Martinez-Giron and van 
Woerden, 2011, ENCLOSED PAPER).  Cases were defined as respiratory 
inpatients whose sputum contained protozoa.  The comparison cases did not 
have protozoa identified in their sputum samples.  The comparison identified 
that the presence of monocytes/small macrophages in the sputum sample gave 
a positive predictive value for protozoa of 74.3% (52/70) and a negative 
predictive value of 84.3% (102/121), when monocytes were absent.  The study 
identified that 66.7% (8/12) of patients on oral steroids had protozoa in their 
sputum, compared to 34.6% (62/179) of patients who were not on oral steroids 
(Fisher‟s Exact test p=0.033).  Similarly, in a binary logistic regression model to 
predict the presence/absence of protozoa, those on inhaled steroids had a 
reduced odds of having protozoa in their sputum compared to those on oral 
steroids (odds ratio 0.138; p=0.027).  The commonest reason for prescribing 
oral steroids in respiratory inpatients with a productive cough (as in this study) 
is an acute asthma attack.  We do not have diagnoses for the patients in this 
case comparison study.  However, if we presume that the patients on oral 
steroids had been hospitalised for acute exacerbations of asthma, then asthma 
attacks would be associated with an increased probability of protozoa in sputum.  
Smokers also had a raised odds of having protozoa in sputum, compared to the 
combination of non-smokers and ex-smokers (odds ratio 1.859; p=0.047). 
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3.1.4 Other studies 
The Spanish colleagues have undertaken a literature review which summarises 
the different species of protozoa that have been recovered from patients with 
respiratory infections (Martinez-Girón et al., 2008).  The species of protozoa 
identified in the literature review represent rare organisms reported in small 
case series.  These known species do not appear to the author to be feasible 
candidates for the protozoa that are prevalent in a large proportion of patients 
with asthma, in the studies reported by the author (van Woerden et al., 2011b). 
A potentially more relevant series of papers from Eastern Europe has been 
identified which describe trichomonas-like protozoa in the respiratory tract.  This 
series of papers state that these organisms are relatively common in sputum but 
are difficult to detect (Kutisova et al., 2005, Hersh, 1985, Mallat et al., 2004, 
Duboucher et al., 2007, Duboucher et al., 2008, Mantini et al., 2009). 
3.1.5 Speculative hypotheses 
A series of letters (see Appendix 3) have been published by the author and 
colleagues proposing a number of speculative hypotheses in relation to the 
above findings (Martinez-Giron et al., 2008, Martinez-Giron and van Woerden, 
2009a, Martinez-Giron and van Woerden, 2010, Martinez-Giron and van 
Woerden, 2009b).  The author hypothesised that these protozoa could be 
present in mite faeces and subsequently inhaled by some patients.  Patients with 
asthma might be more susceptible to colonisation of the respiratory tract by 
such protozoa.  This in turn may have an adjuvant-like effect on the immune 
system, increasing the response in asthma patients to other antigens such as 
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pollen etc. (Martinez-Giron et al., 2008, Martinez-Giron and van Woerden, 
2009a). 
Another speculative hypothesis has been proposed by the author and colleagues 
to the effect that one of the commonest allergens (Der p1), which is known to be 
present in the intestine of dust mites and in mite faecal pellets, could be 
protozoal in origin rather than secreted by the mite intestine as has widely been 
assumed (Martinez-Giron and van Woerden, 2009b, Martinez-Giron and van 
Woerden, 2010).  Further work is underway to test this hypothesis. 
Although these hypotheses are speculative, a similar hypothesis has been 
proposed in relation to Kawasaki‟s Disease (Hamashima et al., 1982).  In this 
study, rickettesia-like bodies were shown to be more common in the intestines 
of mites taken from the homes of patients with Kawasaki‟s Disease.  The authors 
of this paper hypothesised that dust mite faeces containing the rickettesia-like 
organisms had been inhaled and caused the disease in the affected patients. 
3.2 Original contribution made 
In these case studies, the author has facilitated interdisciplinary work across the 
disciplines of epidemiology, microbiology, and clinical medicine and provided the 
driving force behind the testing of the hypotheses presented in this thesis. 
Protozoa have been shown for the first time to be more prevalent in induced 
sputum from asthma patients living in the community than in non-atopic 
controls.  Protozoa have been shown to be common in spontaneously produced 
sputum from hospital inpatients.  Inpatients on oral steroids have been shown to 
have a much higher prevalence of protozoa in their sputum (66.7%) compared 
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to those who are not on oral steroids (34.6%).  Similarly, smokers and ex-
smokers have been shown to have a higher prevalence of protozoa (45.1%) 
compared to non-smokers (30.3%). 
The research presented has demonstrated that smokers have raised odds 
(1.859) of protozoa in sputum compared to non-smokers and ex-smokers.  In 
absolute terms, 23.6% of non-smokers had protozoa in their sputum whereas 
41.7% of smokers/ex-smokers had protozoa in their sputum.  Similarly, the 
research presented has demonstrated that those who were not on either oral or 
inhaled steroids had reduced odds (0.267) of protozoa in sputum compared to 
those on oral steroids.  In absolute terms, 66.7% of inpatients on oral steroids 
had protozoa in their sputum whereas 34.6% of inpatients with respiratory 
symptoms who were not on oral or inhaled steroids had protozoa in their 
sputum. 
3.3 Methodological considerations 
The author has led the development and design of the studies presented.  Skills 
have been developed in bidding for research funding, applying to Research 
Ethics Committees, obtaining approval from NHS Research and Development 
Departments, and employing staff to facilitate patient recruitment and sputum 
collection. 
Practical difficulties that have been encountered have been successfully 
resolved.  For example, we found it extremely difficult to obtain induced sputum 
from non-atopic controls.  This issue had not been highlighted in the existing 
35 
 
literature, but it has significant implications for the use of non-atopic controls in 
future studies that collect induced sputum. 
The case series and case control studies would all have benefited from larger 
sample sizes and tighter case definitions.  In particular, the diagnosis of asthma 
could have been more fully assessed by lung function, skin prick tests to a range 
of allergens or RadioAllergoSorbent Testing (RAST) for total and specific IgE to a 
range of common allergens.  It would also have been helpful to have similar 
assessments undertaken on control participants.  Access to more than one set of 
controls drawn from different populations would also have reduced the risk of 
bias that is inherent in case control studies. 
3.4 Discussion of findings 
At present, it is unclear whether the protozoa identified in the respiratory tract of 
asthma patients have any pathological significance.  The organisms could simply 
be commensal organisms that have no wider significance.  However, it is 
possible to speculate that, even in a proportion of respiratory patients, the 
protozoa may have a role to play, perhaps by altering the Th1/Th2 balance as 
part of the wider immune response to inhaled antigens such as pollen etc. 
(Jacquet, 2011b, Jacquet, 2011a).  This could be measured in a future study.  It 
is also possible that individuals with asthma differ from non-asthmatic 
individuals in terms of their genetic susceptibility to colonisation by respiratory 
microbiota. 
The proposal that contaminating microbial compounds, present in or on dust 
mites, may play a role as adjuvant factors and encourage a Th2-biased allergic 
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response is supported by a recent review (Jacquet, 2010), which quotes 
previous work by the author (van Woerden, 2004).  A current model of the 
possible role of dust mites and their ecological role in asthma, taken from this 
review, is provided in Figure 5 below. 
 
FIGURE 5: ALLERGENS AND ORGANISMS PRESENT IN AND ON MITES 
THAT MAY AFFECT ASTHMA (JACQUET, 2010) 
 
The discovery that stomach ulcers were related to infection with Helicobacter 
pylori has renewed interest in the potential role that infectious agents may play 
as part of a causal web contributing to chronic disease (Marshall et al., 1985).  
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The interaction between dust mites and asthma described by Voorhorst 
epitomises the complex relationships that exist between human beings and other 
life forms (Voorhorst et al., 1967).  It is possible that many similarly complex 
relationships are yet to be discovered. 
There is increasing evidence that a large number of protozoa cannot be cultured 
using existing techniques and have not been described in existing taxonomies 
(Jeon et al., 2008, Stoeck et al., 2006).  A wide range of protozoa have been 
discovered in studies of the biosphere using molecular techniques and have been 
submitted to international databases such as the National Centre for Biotechnical 
Information (Anon., 2011) but have not been otherwise characterised. 
There is increasing recognition that human beings carry a large microbiota in the 
gut, on the skin and on other mucosal surfaces (Hilty et al., 2010) and that the 
respiratory tract has a distinct microbiota (Rogers et al., 2005, Tunney et al., 
2008).  These populations of microbiota interact with the immune system.  It 
has been shown that microbiota affect immune responses in the lungs (Rogers et 
al., 2009, Hilty et al., 2010) and that exposure to microbiota at one mucosal 
surface can affect allergic responses at another mucosal surface (Cogen et al., 
2008, Round and Mazmanian, 2009, Dethlefsen et al., 2006). 
The research on microbiota and immune response disorders such as asthma 
raises the general question as to how a postulated aetiological association can 
be proven.  Historically, Koch-Henle postulates  (Inglis, 2007a, Marshall et al., 
1985) were used to demonstrate that a given infectious agent had an 
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aetiological role in a given disease (Inglis, 2007b)1.  Identification of organisms 
as the cause of disease where no culture method is known is more challenging 
(Evans, 1976).  The emergence of molecular methods for the identification of 
organisms has led to the proposal of „molecular Koch's postulates' (Inglis, 
2007b).  This approach builds an argument for a causal relationship based on 
the presence of evidence to support the following series of assertions: 
“congruence or reproducible correlation of a taxonomically defined life form with 
the clinico-pathological and epidemiological features of infection;  consistency of 
the demonstrable biological response in the subject to an encounter with the 
prospective infective agent; progressive or cumulative dissonance as an 
explanation for pathophysiological processes at every known level of biological 
organization in the subject; curtailment of that pathophysiological process on the 
deliberate introduction of a specified biomedical intervention”.  This approach 
may be helpful in exploring the possible role of protozoa in asthma in the future.  
Other frameworks, such as the Bradford-Hill criteria for causality (Brownson et 
al., 2010), and the study design underpinning the evidence are also relevant 
(Sackett, 1997, Guyatt et al., 2008, Guyatt et al., 2011). 
                                       
1 The Koch-Henle postulates are: the micro-organism must be found in abundance in all organisms suffering 
from the disease, but should not be found in healthy organisms; the micro-organism must be isolated from a 
diseased organism and grown in pure culture; the cultured micro-organism should cause disease when 
introduced into a healthy organism; the micro-organism must be re-isolated from the inoculated, diseased 
experimental host and identified as being identical to the original specific causative agent. 
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3.5 Unpublished findings related to molecular analysis of 
sputum samples 
Further work has been undertaken to assess whether the protozoa seen by light 
microscopy can be identified in sputum samples using molecular techniques.  To 
date this work has been unsuccessful.  Potential reasons for this include the 
possibility that more than one species of protozoa is present.  This would result 
in the signal for each separate species of protozoa falling below the threshold of 
detection.  Inhibitory compounds could be present in the samples and prevent 
DNA amplification.  The microscopic identification of putative protozoa could 
even represent misidentification of other phenomena such as a combination of 
cell debris and fungi, although the author believes that this is unlikely. 
Ethical approval was obtained by the author to allow the sputum samples 
collected by the author in Wandsworth, London, to be used for molecular 
analysis using variations in 18S rRNA to characterise different species of 
eukaryotes present in the samples.  Sputum samples, taken from microscope 
slides, were combined to form one set of sputum from asthma patients and one 
set of sputum from control subjects.  Between two and five areas were excised 
from each microscope slide using a Zymoresearch pinpoint system providing a 
total sputum sample of around 5 mm3.  DNA was extracted and then amplified 
using generic 18S primers and standard amplification techniques.  The two 
samples were tagged and then analysed using a 454 pyrosequencer by a 
company in Texas, USA.  The DNA sequences read by the pyrosequencer were 
compared to databases of known sequences to determine, in a semi-quantitative 
way, the percentage of DNA in each of the two samples derived from known 
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species of eukaryotic organisms.  The practical laboratory work on the samples 
was undertaken by research colleagues in the School of Biosciences, Cardiff 
University (Dr C Gregory, Dr R Brown, and Dr J Marchesi). 
This study has demonstrated differences in the range of fungi that were present 
in sputum samples taken from asthma patients and non-atopic controls.  Table 9 
lists the fungi found in the samples from the patients with asthma and the 
controls where the difference in the percent of total reads was > 4%. 
TABLE 9: PERCENT OF DNA READS IN THE SPUTUM OF ASTHMA 
PATIENTS AND NON-ATOPIC CONTROL PARTICIPANTS WHERE THE 
DIFFERENCE IS > 4% 
Name 
Non-atopic control participants 
(Percentage of reads) 
Asthma patients 
(Percentage of reads) 
Eremothecium sinecaudum 41.3 1.0 
Systenostrema alba 23.6 0.0 
Cladosporium cladosporioides 14.5 0.1 
Vanderwaltozyma polyspora 6.8 0.1 
Grifola sordulenta 0.0 4.5 
Termitomyces clypeatus 0.0 7.1 
Malassezia pachydermatis 0.0 21.7 
Psathyrella candolleana 0.0 27.3 
 
The difference between the two samples was tested by Dr Julian Marchesi, 
Cardiff University using Unifrac (Lozupone et al., 2006).  A statistically 
significant difference in the pattern of fungi that were present in the respective 
samples was demonstrated using the Phylogenetic (P) test (p <0.0001). 
The fungi Malassezia pachydermatis, which had a higher prevalence in patients 
with asthma, has a known association with atopic dermatitis (Gaitanis et al., 
2012).  Two of the fungi most commonly found in the sputum of asthma patients 
(Termitomyces clypeatus and Psathyrella candolleana) represent members of the 
mushroom family (Khowala et al., 1993).  The latter has been found in indoor 
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dust (Pitkaranta et al., 2008) and one can speculate that the fungi have been 
inhaled from the environment.  However, no obvious associations were identified 
in the published literature between the other fungi identified and asthma.  It is 
possible that most of the fungi identified could have come from a single 
individual, or a small number of individuals, whose samples were heavily 
colonised by fungi. 
Except for Cladosporium, the species identified in induced sputum are not 
commonly found in air samples examined using standard culture techniques 
(Burr et al., 2007).  Analysis of air samples using molecular techniques may 
demonstrate that these species are commonly present in the air, but this 
research has not been undertaken so far.  The presence of a wide range of fungi 
in sputum suggests that future studies of induced sputum should simultaneously 
collect air samples to assess the extent to which fungal species in sputum 
resemble those in the immediate environment. 
The molecular methods used to date have not demonstrated the presence of 
protozoa, although it is possible to speculate that some of the genetic sequences 
ascribed to fungi may be protozoal in origin.  To pursue this hypothesis further, 
there is a need to isolate significant numbers of protozoa from pooled samples 
and develop a sensitive and specific molecular test for one or more species of 
protozoa that may be present.  Samples from individuals, containing very small 
amounts of DNA, could then be tested.  A new research protocol has been drawn 
up using a range of techniques to physically isolate and characterise any 
protozoa in fresh sputum samples.   
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4 Conclusion 
This thesis has presented two series of published papers relating to two atypical 
respiratory organisms.  The first series of papers followed a cohort of patients 
exposed to C. burnetii in an outbreak of Q fever, examined the effectiveness of 
case finding, assessed the prevalence of post Q fever chronic fatigue in the 
exposed cohort at six years follow up, and undertook a comparison of the 
consistency of Q fever micro-immunofluorescent tests across three international 
reference laboratories.  The series of papers has demonstrated a potential long 
lasting risk from straw board, the prevalence of post Q fever chronic fatigue, the 
possibility that depression is a long-term sequelae of Q fever infection, and the 
need for better international standards for Q fever immunofluorescent tests.  
There is also a need for an internationally agreed set of reference strains of C. 
burnetii, and a system of international cross-checking of samples. 
The unpublished work on Q fever highlighted the weaknesses of single sample 
CFT tests, demonstrated the severity of chronic fatigue in some patients six 
years later, highlighted the association between smoking and chronic Q fever 
symptoms, and provided a regression model that could be used as an algorithm 
to help distinguish Q fever from other illnesses based on clinical symptoms.  A 
small cohort of eight patients with serological evidence of chronic Q fever has 
also been identified for ongoing follow up. 
The second series of papers investigated a controversial hypothesis that 
flagellated protozoa are more common in the sputum of patients with respiratory 
disease.  The papers have demonstrated the presence of protozoa in the sputum 
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of patients in the UK as well as in Spain, an increased odds of observing 
monocytes or small macrophages in the sputum of patients with protozoa, an 
increased odds of the presence of protozoa in the sputum of patients with 
asthma in the community, and a raised odds for the presence of protozoa in the 
sputum of hospital inpatients with respiratory disease who were smokers or who 
were on oral steroids.  Some unpublished work using molecular methods to 
examine sputum for eukaryotes has also been presented which identifies 
differences in the percentage of DNA reads for fungi present in asthma patients 
and control subjects. 
The case series and case comparison studies presented are relatively small.  In 
retrospect, these studies would have been strengthened by having larger sample 
sizes, more extensive analysis of disease characteristics, and the use of more 
than one set of controls to reduce the risk of selection bias.  
4.1 Potential for future research 
The work presented points to several lines of research on Q fever.  There is a 
need to follow up the cohort of eight patients with serological but not clinical 
evidence of chronic Q fever.  An RCT of the use of long-term antibiotics in 
patients with post Q fever Chronic Fatigue would be justified, with both 
predetermined serological and clinical end-points, as this is a chronic disabling 
condition, with no established treatment.  Further work to develop international 
reference standards is also needed (Kampschreur et al., 2012). 
The aetiological hypotheses related to flagellated protozoa are the subject of on-
going research by the author using molecular methods to identify and 
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characterise the microbiota in the respiratory tract and examine the impact that 
this has on respiratory health and disease.  It is hoped that this will result in the 
development of rapid DNA based tests for relevant species of protozoa that can 
be used to test the sputum of patients with respiratory symptoms or disease.  
Similar methods are being pursued in relation to the microbiota that exists 
within dust mite faeces, and to test the hypothesis that protozoa present in mite 
faeces could be the source of Der p1, as has been proposed in the letters 
attached in Appendix 3.  It is fully recognised that these hypotheses are highly 
speculative.  However, even if the hypotheses in Appendix 3 are ultimately 
disproved, it is likely that this line of research will yield further information 
regarding the microbiota in a range of environments that are relevant to human 
health. 
Further work may well suggest that a RCT is undertaken to test the hypothesis 
that eradication of protozoa from induced sputum samples with an appropriate 
anti-protozoal agent reduces asthma symptoms (Miranda, 1980, Ribas et al., 
2007).
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the initial Q fever outbreak, which was used in a Part II report for the Faculty of 
Public Health of the Royal College of Physicians of Ireland. 
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research leading to each publication is provided in the table below. 
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An outbreak of Q fever occurred in South Wales,
United Kingdom, from July 15 through September 30,
2002. To investigate the outbreak a cohort and nested
case-control study of persons who had worked at a card-
board manufacturing plant was conducted. The cohort
included 282 employees and subcontractors, of whom 253
(90%) provided blood samples and 214 (76%) completed
questionnaires. Ninety-five cases of acute Q fever were
identified. The epidemic curve and other data suggested an
outbreak source likely occurred August 5–9, 2002.
Employees in the factory’s offices were at greatest risk for
infection (odds ratio 3.46; 95% confidence interval
1.38–9.06). The offices were undergoing renovation work
around the time of likely exposure and contained straw
board that had repeatedly been drilled. The outbreak may
have been caused by aerosolization of Coxiella burnetii
spore-like forms during drilling into contaminated straw
board.
Qfever is an infection caused by the bacterium Coxiellaburnetii. The organism is found in most parts of the
world and is endemic in wild and domestic animals,
rodents, and arthropods, which provide a reservoir for
infection (1). Most outbreaks have been associated directly
or indirectly with farms or farm animals, but urban out-
breaks have been described (2,3). Infected animal birth
products can cause outbreaks of Q fever, and an infected
placenta can contain as many as 109 organisms per gram
(4). C. burnetii produces a spore-like form, which can sur-
vive for months or years before being inhaled and causing
infection (5,6). The infective dose can be as low as one
organism; therefore, large outbreaks can be caused by a
small source (7). A review of the literature was undertaken
by one of the authors (available from H.C. van Woerden).
This investigation identified 79 outbreaks reported in 48
articles in English language journals. An additional 44
papers in other languages were identified in a literature
review by Williams (7) and a further 40 German outbreaks
were identified in a literature review by Hellenbrand et al.
(8). The literature review suggested that most outbreaks are
associated with primary or secondary aerosols that arise
around infected animals or contaminated fomites (5,9).
Approximately 70 cases of Q fever are identified in the
United Kingdom each year as a result of routine surveil-
lance (R. Smith, pers. comm., Zoonosis Surveillance,
Communicable Disease Surveillance Centre, Wales).
However, seroprevalence studies indicate that approxi-
mately 27% of farmers and 10% of the general population
have antibodies, which suggests previous exposure to the
organism; this finding does not appear to have changed
substantially during the last 45 years (10,11). We report an
investigation of an outbreak of Q fever at the premises of
a manufacturer of cardboard packaging materials in
Newport docks, South Wales, in the summer of 2002.
Methods
Description of the Outbreak
A possible outbreak of atypical pneumonia was report-
ed to the local public health department on September 12,
2002, by a physician who reported that other employees at
the patient’s workplace had had similar symptoms. The
outbreak was verified, an outbreak control team assem-
bled, and a case definition agreed on (12). By September
15, 2002, a total 12 potential patients had been identified
and the first case confirmed as Q fever. The investigation
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was begun by contacting all relevant hospital clinicians
and general medical practitioners in the Gwent area and
requesting that they supply blood samples from any
patients who had symptoms compatible with Q fever. 
Epidemiologic Investigation
Several hypotheses were explored. An outbreak could
have occurred in the wider community, and employees
could have been infected by contaminated straw, hay, or
compost; wild or feral animals; or domestic animals, par-
ticularly pregnant or newborn animals. Contamination
could have been through sources brought into the factory,
which included the following: contaminated personal
belongings; contact with a contaminated source on the
docks, which were on the way to work; windborne spread
from infected animals on nearby farms; windborne spread
from goods passing through the docks; animals or animal-
based feed; contaminated hay, straw, or farm vehicles;
sources in the factory premises; wooden delivery pallets
contaminated with chicken carcasses returned to the facto-
ry; infection passed by red mites biting infected seagulls
nesting on the roof, which then may have bitten staff in the
factory; airborne spread from a cat that had given birth
near the factory 2 years previously; airborne spread of con-
taminated dust generated by the renovation work; dust pre-
viously contaminated by an infected animal, bird, rodent,
or bat; or contaminated straw or straw board aerosolized
during drilling or removal. 
We obtained data from a variety of sources, including a
questionnaire survey, laboratories, clinicians, and factory
management. A list containing details of the workforce and
possible, past, and confirmed cases was developed and used
to construct an epidemic curve. Data on place of work pro-
vided by factory management were used to calculate attack
rates. Details were also collected on persons who had been
on site for a limited number of days to help pinpoint the
onset of the outbreak. Employees working on the factory
floor were examined to determine whether a pattern
occurred in the infected patients by calculating the relative
risks for employees at each machine on the factory floor.
Two clinics were held at the factory on September 23
and 30, 2002, where blood samples were obtained from
and questionnaires were completed by employees and sub-
contractors who had worked at the factory at any time from
July 15, 2002, through September 30, 2002. Data from the
questionnaires were analyzed by using a nested case-con-
trol design, where cases were defined as confirmed cases
and controls were defined as noncases. The questionnaire
explored risk factors in three categories: possible exposure
in the community, in the docks or on the route to work, and
at work.
Case definitions were applied to employees and sub-
contractors who had worked at the factory at any time from
July 15, 2002, through September 30, 2002. A confirmed
case was defined as phase 2 immunoglobulin (Ig) M >320
or fourfold rise in complement fixation tests (CFT) titer or
IgM 20–160 + phase 2 IgG ≥320. A past exposure was
defined as phase 2 IgG but no phase 2 IgM. A noncase
(control) was defined as a CFT of <8 + negative phase 2
IgM and IgG + either no symptoms or onset of symptoms
>7 days before blood sample or (in which the onset of
symptoms was within 7 days of first sample) two consec-
utive blood samples with a CFT of <8 + one negative phase
2 IgM and IgG. A possible case was defined as all remain-
ing cases.
Data were analyzed with EpiInfo (v. 6.04, Centers for
Disease Control and Prevention, Atlanta, GA), Excel 97
(Microsoft, Redmond, WA), and Stata (v. 7, Stata
Corporation, College Station, TX) software. Possible cases
in patients and persons with evidence of past exposure
were excluded from the nested case-control study. The
analysis also excluded responses of “not sure” from odds
ratio (OR) calculations. We calculated Mantel-Haenszel
OR with exact 95% confidence limits (CI) (13). 
Microbiologic Investigation
Complement fixation tests for phase 1 and phase 2 anti-
bodies were performed at the Public Health Laboratory
Service, Cardiff. IgM and IgG immunofluorescent assays
were carried out on the samples by the Centre for Applied
Microbiological Research (CAMR), Porton Down, UK.
Laboratory staff monitored all requests for Q fever sero-
logic testing from general practitioners and hospital clini-
cians to identify any additional cases that might be linked
with the outbreak.
Environmental Investigation
Environmental information on the factory was gathered
by environmental health officers and other members of the
outbreak control team during site visits on September 23,
2002, and September 30, 2002. Management representa-
tives of several other premises in or near the docks were
interviewed. 
On October 11, 2002, an environmental scientist col-
lected 17 random environmental samples of straw and dust
from inside and outside the factory premises. The samples
were sent for polymerase chain reaction (PCR) testing at
CAMR.
Results
Epidemiologic Investigation
A total of 222 employees and 60 subcontractors were
working in the factory complex from July 15 through
September 30, 2002. Questionnaires were completed by
214 (75.9%) of these 282 persons. Of the 253 persons who
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were tested, we identified 95 (37.5%) confirmed cases of
Q fever, 42 possible cases, 8 cases of past exposure, and
108 noncases. Four persons refused blood tests but com-
pleted a questionnaire. Data for the nested case-control
analysis were available on 75 (78.9%) of the 95 confirmed
cases and 101 (93.5%) of the 108 noncases. The frequen-
cy and duration of symptoms are shown in Table 1 and
Figure 1. Ten participants were still ill when questioned,
and 5 did not provide a date of onset of symptoms. Five
patients (5.3%) were admitted to the hospital with pneu-
monia. Some patients experienced fatigue. However, the
clinical impression of one of the authors involved in follow
up of patients was that very few neurologic symptoms
occurred during this outbreak, compared to a previously
reported U.K. outbreak (14). Further analysis of clinical
symptoms is being prepared as a separate paper.
The epidemic curve for 49 confirmed cases where the
date of onset of symptoms was reliably known is shown in
Figure 2. A peak incidence occurs around September 1,
2002. Based on an incubation period of 5 to 40 days (1,5),
these data suggest that almost all the cases can be account-
ed for by an exposure from August 7 to 11, 2002.
Seven confirmed patients were only present in the fac-
tory on 2 or 3 days. All these persons were present in the
factory and potentially exposed to infection from August 5
through August 9, 2002.
An analysis of home postal codes of 71 participants
with Q fever who completed the questionnaire showed no
discernible pattern and indicates that our participants were
not part of a larger Q fever outbreak with a common source
in the community. Details of place of work within the fac-
tory complex were available for participants with 61 con-
firmed cases and 81 controls. No cases occurred among
persons working exclusively outside the factory floor or
office block. In addition, no cases were identified among
seven participants working in a separate design office, one
employee working exclusively in the dispatch building, or
five sales representatives who only called into the office on
an occasional basis (Table 2). The OR for having a case in
office staff compared with other staff was 3.46 (95% CI
1.38–9.06). ORs for groups of staff working in all other
areas were <1 (Table 2).
The relative risks of having a case of Q fever among the
cohort of employees working at different machines on the
factory floor are shown in Figure 3. The balcony in Figure
3 is not drawn to scale. It overhangs the adjacent machines
where the relative risk to workers was zero. The relative
risk for infection was greatest among people who worked
in the center of the factory floor outside the shadow of the
overhanging balcony; the risk for infection dropped
towards the sides of the building.
Eighty-three percent of confirmed cases were in men, a
similar male-to-female ratio to that of the cohort as a
whole, and median age was 44 years (range 22–60 years).
Questionnaire data indicated that infected employees did
not own animals that had given birth or had a miscarriage
nor had these employees had any contact with the birth
products of animals. One subcontractor, who cleaned win-
dows at the factory, also worked on a farm and had been in
contact with animals that had given birth, but the evidence
did not suggest that any of these had been infected with C.
burnetii. Additionally, the serologic tests for this employee
were negative for Q fever, and the dates on which he visit-
ed the factory suggest that his clothing or possessions
could not have been the source of the outbreak.
Case-patients were much more likely than controls (OR
5.86; 95% CI 0.55 to 291.88) to recall coming across a hay
lorry entering or leaving the docks while on their way to or
from work. Adjusting for cases in those whose office was
refurbished reduced the OR in those who saw a hay lorry
(OR 3.00; 95% CI 0.28–31.80). Employees whose offices
had been refurbished were at greatest risk for infection
(OR 2.60; 95% CI 0.77–9.57). Employees who described
themselves as “never near an external door or window”
were more likely to be infected than those who worked
“near an external door or window on most days” (OR 1.98;
95%CI 0.72–5.56). Living on a farm appeared slightly pro-
tective (OR 0.35; 95% CI 0.01–4.53) as did the regular
handling of compost (OR 0.14; 95% CI 0.00–1.03).
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Figure 1. Duration of illness in symptomatic Q fever patients,
Newport, Wales, August–September 2002.
Table 1. Frequency of symptoms in 55 symptomatic patients with 
confirmed cases of Q fever, Newport, Wales, August–September 
2002 
Symptom Yes (%) Not sure 
Fever 41 (75) 1 
Sweats 53 (96) 0 
Headache 51 (93) 1 
Weight loss 26 (47) 2 
Cough 24 (44) 0 
Shortness of breath 25 (45) 2 
Joint pain 44 (80) 3 
Chest pain 20 (36) 5 
Jaundice 4 (7)a 5 
aThese responses represent a misunderstanding of the term jaundice, 
since none of these persons had clinical jaundice. 
However, none of these findings, or those in Table 3,
reached statistical significance value of 5%.
The work undertaken by the seven participants with the
shortest incubation times was examined for unusual char-
acteristics. A higher proportion of those with a short incu-
bation time were women (three of seven) when compared
with the general population. Four of the seven participants
worked in offices that had been refurbished, and the
remaining three worked on the factory floor. Their dura-
tion of illness varied from 4 to 14 days.
Microbiologic Investigation
Two hundred and fifty-three participants (89.7%) pro-
vided blood samples. Some participants had only one sam-
ple taken and others had up to four additional samples
taken from September through December 2002 at primary
care or hospital clinics. A summary of CFT and IgM results
is shown in Tables 4 and 5. 
As a result of informing general practitioners in the area
of the outbreak, more than twice the normal numbers of
general practitioner requests for Q fever serologic testing
were received. Hospital samples submitted for Q fever
serologic testing were also monitored. Our monitoring
identified one patient with a chronic case of Q fever and
one patient with an acute, neither were associated with this
outbreak. No C. burnetii was identified by PCR testing the
straw board and dust samples that were obtained from the
factory. 
Environmental Investigation
The factory consists of several buildings. The main pro-
duction area consists of a large, rectangular open-plan
hanger with an elevated office block at one end of the rec-
tangle (Figure 3). The office block was undergoing exten-
sive renovation work at the time of the outbreak. This
involved drilling >100 holes in the straw board ceiling to
allow the attachment of a new suspended ceiling. Some
internal walls made of straw board were also removed. A
temporary corridor was created from plastic sheeting
which ran through the area being renovated but did not
form a complete seal. No respiratory protection was used
by the contractors or the workforce at any stage. The cor-
ridor was in constant use by staff in adjacent offices.
Office staff and factory floor workers who visited the
offices consequently had some exposure to dust generated
by the renovation work.
The layout of the factory is consistent with the possibil-
ity of disseminating contaminated dust from the renovated
offices to the factory floor. The office block ran along the
length of one end of the factory floor. Double-swing doors
led from the second floor renovated offices onto an over-
hanging internal balcony 30 feet above the large open-plan
factory floor (Figure 3). The factory production area had
no windows and no air-conditioning system. A dust extrac-
tion system existed around some of the machines on the
factory floor to collect waste cardboard. The lack of win-
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Figure 2. Epidemic curve for 49 confirmed cases in Q fever out-
break, Newport, Wales, August–September 2002.
Table 2. Attack rates and odds ratios (OR) for different areas of work at factory implicated in Q fever outbreak, Newport, Wales, 
August–September 2002  
No. of persons working in area  No. of persons working elsewhere  
Category Cases Controls  Attack rate (%)  Cases Controls  Attack rate (%)  OR (95% CI) a 
Production/factory floor  35 52 40.2 26 29 47.3 0.78 (0.36–1.57) 
Dispatch 0 1 0 61 80 43.3 0 (0–71.79) 
Dispatch/factory floor  4 4 50.0 57 77 42.5 0.68 (0.14–2.68) 
Office 20 10 66.7 41 71 36.6 3.46 (1.38–9.06) 
Production -based but 
sometimes in the office  
1 2 33.3 60 79 43.2 0.66 (0.01 –12.96) 
Design 0 7 0 61 74 45.2 0 (0–0.88) 
Sales representatives  0 5 0 61 76 44.5 0 (0–1.42) 
Dispatch but sometimes 
in the office  
1 0 100 60 81 42.6 Undefined 
Total 61 81 43.0     
aCI, confidence interval.   
dows in the factory production area and the dust extraction
system almost certainly caused a degree of negative pres-
sure in the factory. This condition would draw air in
through the double doors leading from the renovated office
area and onto the factory floor. 
Discussion
Environmental and epidemiologic evidence suggests
that this outbreak was associated with the renovation of an
office block within a cardboard manufacturing plant. One
potential source identified was straw board in walls and
ceilings disturbed by the renovation work. If straw board
had been contaminated at some time in the past with a con-
centrated source of C. burnetii, drilling into this could have
produced a cloud of dust containing large numbers of C.
burnetii sporelike forms. Dust containing C. burnetii spore-
like forms could have been sucked through the balcony
doors from the renovated offices, fallen onto the workforce
below, and inhaled by those infected. Workers could also
have been infected when visiting the personnel or accounts
offices situated adjacent to the renovation work.
No record of visits to these departments exists, which
would allow this hypothesis to be further assessed.
However, the hypothesis is supported by a number of fac-
tors. The pattern of relative risk for infection in groups of
participants at different machines on the factory floor is
consistent with this hypothesis. The highest relative risks
are in the center of the factory close to the balcony, while
the lowest risks are in the areas at the sides and far end of
the factory floor. The overhanging balcony may have shel-
tered employees at some of the machines from any contam-
inated dust falling from above. Raised ORs for infection in
employees who were decanted into neighboring offices
because their offices were being renovated, and in office
staff whose offices had been refurbished, also implicate the
renovation work as the source of the outbreak.
The timing of the installation of the new suspended
ceiling (July 17–August 9, 2002) is consistent with an out-
break source near August 5 through August 9. The raised
OR in persons rarely near an open window or door com-
pared with those often near an open window or door and
the lack of cases among those who worked in the separate
design office, or among sales representatives, suggest that
the source of the outbreak was inside the factory.
The respirable dust fraction that is most pathogenic is
generally invisible to the naked eye (15,16). We do not
have a good proxy for exposure in this outbreak, and con-
sequently the issue of a dose response has not been
addressed. Exact place of work probably did not closely
correlate with exposure as many staff members move
around the building as part of their work.
Potential Contamination of the Straw Board
Straw board could have been contaminated either
before or after manufacture. Investigating the process used
to make the straw board indicated that the low pressures
and temperatures involved would not kill any fungal
spores present in the straw. If straw board becomes wet,
these fungal spores often sprout and damage the board.
The straw used to produce the board was stored in large
Dutch barns and would have been accessible to rodents,
cats, and other animals. Some evidence exists that a num-
ber of cases of Q fever were occurring around 1950 in the
English county where the straw board was manufactured
(17) and that the straw board was probably manufactured
from 1950 to 1953. C. burnetii sporelike forms are
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Figure 3. Relative risks for employees at various machines on the
factory floor in Q fever outbreak, Newport, Wales,
August–September 2002.
Table 3. Odds ratios (OR) for different risk factors in Q fever outbreak, Newport, Wales, August–September 2002 
No. of persons exposed 
 to risk factor 
No. of persons not exposed  
to risk factor 
Exposure at work Cases Controls Cases Controls OR (95% CI) 
Office refurbished 24 23 6 15 2.61 (0.77–9.57) 
Never near an external door or window/near a 
window or door most days 
13 10 40 61 1.98 (0.72–5.56) 
Smoker/never smoked 15 35 42 48 0.49 (0.22–1.08) 
Saw hay lorry on the docks 4 1 56 82 5.86 (0.55–291.88) 
Live on a farm 1 3 72 76 0.35 (0.01–4.53) 
Regularly handle compost 1 9 68 83 0.14 (0.00–1.03) 
Contact with animal births or miscarriages 0 6 39 54 0.00 (0–1.26) 
aCI, confidence interval. 
resilient. They can withstand pressures of up to 20,000
lb/in2, elevated temperatures, desiccation, osmotic shock,
UV light, and chemical disinfectants (18). However,
experimental studies of the survival of C. burnetii spore-
like forms have not demonstrated survival beyond 8 years
(Table 6) (5,6). Whether experiments for longer durations
were undertaken is not clear from the source documents.
Although not directly comparable, Bacillus anthracis and
Clostridium tetani spores are known to survive for many
years. For example, B. anthracis spores have been record-
ed as surviving for 71 years on dried silk threads (19).
Alternatively, the straw board could have been contam-
inated after manufacture by the feces, urine, birth products,
or a corpse of an infected rodent that gained access to the
inner layer of a straw board. Some holes were drilled in the
straw board ceiling in 1982 and 1983, which could have
provided a point of entry. Rodents are considered an
important potential source of C. burnetii, and in one U.K.
serosurvey, 34% of wild brown rats (Rattus norvegicus)
had antibodies suggesting previous exposure to C. burnetii
(20). The placentas of common rodents can also contain
large numbers of C. burnetii sporelike forms (21) and
could contaminate straw.
Test results of environmental samples in this outbreak
were, however, negative. This finding could have occurred
for a number of potential reasons. The samples were col-
lected by persons who did not have detailed knowledge of
the outbreak investigation, and the samples tested were
minute in comparison to the quantity of straw disrupted
during the renovation work. Concentration of potential
bacterial contaminants was attempted in the PCR tests, but
analysis was performed on small aliquots of extract, and
bacterial DNA could therefore easily have been missed.
The PCR test used was also experimental, although the
protocol followed was similar to that used in Australia,
France, and Germany. A delay of 2 months occurred
between the dates when employees were probably exposed
to C. burnetii and when environmental dust samples were
collected. Consequently, contaminated dust may have been
dispersed or cleaned up in the interim. In previous out-
break investigations, test results of environmental air or
straw samples for C. burnetii have also more often been
negative (15,22–23) than positive (4,24). The environmen-
tal sampling was, therefore, like looking for a “needle in a
haystack.”
Other Hypotheses
We considered a range of alternative hypotheses but did
not find any evidence to support them. For example, wind
speeds were recorded routinely by the harbor authority but
were very low during the week of August 5 through August
9, 2002, which makes windborne spread from the nearest
farmland, 1 1/2 to 3 miles away, unlikely. No other poten-
tial wild or domestic animal sources were identified.
Animals or animal products had not been moved through
the docks in recent years. A feral cat had given birth in an
adjacent building 1–2 years previously. One of the kittens
had been adopted by an employee. However, the em-
ployee’s serologic testing for Q fever was negative. If the
feral cat had been infected with Q fever, the employee
would most likely have had evidence of past exposure to
C. burnetii. In addition, the factory strongly emphasizes
controlling vermin as some of their cardboard packaging is
used as secondary packaging in the food industry. No cats
or other animals had been identified in or around the build-
ing for several years preceding the outbreak.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 7, July 2004 1287
Q Fever Outbreak in Industrial Setting
Table 4. Summary of highest phase 2 CFT results recorded for each person in the cohort in Q fever outbreak, Newport, Wales, 
August–September 2002a 
Highest CFT AQF cases Noncases Past exposure Possible cases 
<8 4 104 5 35 
8 4 2 3 2 
16 12 1 0 2 
32 14 1 0 2 
64 16 0 0 1 
128 21 0 0 0 
256 17 0 0 0 
512 5 0 0 0 
1,024 2 0 0 0 
Totals (253) 95 108 8 42 
aCFT, complement fixation test; AQF, acute Q fever. 
Table 5. Summary of highest phase 2 IgM results recorded for 
107 persons in the cohorta 
IgM P2 values AQF cases 
Past  
exposure 
Uncertain 
status 
0 1 8  
Low levels 0 0 1 
80 0 0 2 
<60 0 0 0 
160 5 0 2 
320 3 0 0 
640 16 0 0 
1,280 4 0 0 
>1,280 65 0 0 
Total 94 8 5 
aIg, immunoglobulin; AQF, acute Q fever. 
Contaminated fomites can produce secondary aerosols
of C. burnetii sporelike forms (4), and several outbreaks
have demonstrated the possibility of spread on fomites
such as clothing, straw, hay, contaminated shoes, and
building materials (22,25–36). However, unless a mecha-
nism exists to repeatedly reaerosolize the source, fomites
are likely to pose a risk even when they are not heavily
contaminated, and this view is supported by the general
principles that govern the dispersion and settling out of
dust particles or sporelike forms (17,37).
Neither straw nor building material is a common source
of outbreaks of Q fever. However, straw has been suggest-
ed as a possible source in several outbreaks (15,27,38,39).
Two case reports implicate straw: a physician who con-
tracted Q fever after clearing out straw and rubble from his
new moorland home (26) and a businessman who was
cleaning out a barn that had been used for keeping live-
stock 10 years previously but had not been properly
cleaned since (24). Moldy hay from this barn, cultured
using cell growth medium, grew C. burnetii. The renova-
tion of buildings has also been suggested as a source of Q
fever in two previous outbreaks (26,39). The widespread
dispersal of spores in a building has been demonstrated
both by Q fever (disseminated through a large medical
school building) (23) and by anthrax (dispersed through a
post office with an area of 281,387 ft2 and a volume of
approximately 7 million ft3) (40). 
One other alternate hypothesis is that the source of the
outbreak was outside the factory building. Five persons
mentioned having seen a hay lorry in the docks. This
hypothesis was pursued because straw from farm vehicles
had been implicated as a potential cause in a previous local
outbreak of Q fever (2). However, the route taken by the
lorries was never closer than half a mile to the factory. The
lorries passed much closer to several other factories and to
residential areas where several thousand persons would
have had much greater exposure than the workforce at the
factory. Although two Q fever cases were identified in the
neighboring factory, no evidence existed of a wider out-
break involving other premises in the docks or nearby res-
idential areas. The hypothesis that hay lorries passing
through the docks could have caused the outbreak was
known to a number of employees before they completed
the questionnaire, and this finding may therefore be a
result of diagnostic suspicion bias (41). 
Control Measures
Risk assessment and risk management was undertaken
by identifying groups of persons at different levels of risk
and providing relevant advice, temporarily stopping work
in the area of the building considered at greatest risk, and
following identified patients with Q fever. The cardboard
manufactured by the factory was produced at temperatures
that made survival of C. burnetii sporelike forms impossi-
ble so customers were not considered to be at increased
risk. Unlike the straw board, which was produced a very
low temperatures, the cardboard is produced at tempera-
tures that would make survival of C. burnetii sporelike
forms impossible. In addition, the cardboard was only used
for secondary packaging and was therefore not in direct
contact with any food products.
Implications of the Study
Inhaled organic particles are an important source of a
number of occupational diseases (17,42), and risks from
exposure to occupational dust have been addressed by the
U.K. Health and Safety Executive (43,44). Q fever is also
a recognized occupational disease in the United Kingdom
(45) and governed by existing legislation (46), although it
is not a notifiable disease (47). 
Straw is an increasingly popular ecologically friendly
material, and >350,000 houses have been built in the
United Kingdom with this particular type for straw board
as internal partitions. The product has also been exported
around the world. However, this outbreak is the first where
straw board was suggested as a possible source of Q fever.
Further research is needed to fully investigate straw board
in various venues as a potential vehicle in Q fever out-
breaks. Contaminated straw board represents a potential
source of Q fever and should be considered in future out-
break investigations.
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Table 6. Survival of Coxiella burnetiia 
Environment Temperature (°C) Survival 
Wool 15–20 7–9 mo 
Wool 4–6 Approx. 12 mo 
Sand 15–20 4 mo 
Fresh meat Cold storage >1 mo 
Salt meat Not recorded 5 mo 
Skimmed milk Not recorded 40 mo 
Tap water Not recorded 30 mo 
Tick feces Room Conclusive evidence: 586 d
Some evidence: 6 and 8 y 
Not recorded –20 2 y 
Not recorded –65 8 y 
aReferences 5 and 6. 
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SUMMARY
In September 2002, facsimiles were sent to 360 primary-care physicians alerting them to a local
outbreak of Q fever. The physicians subsequently submitted serology samples on signiﬁcantly
more patients than in a previously comparable period in 2001. Facsimile cascade assists eﬀective
communication with primary-care physicians in an outbreak investigation.
Electronic communication is increasingly being used
in the investigation and management of disease out-
breaks : to alert clinicians or intensify surveillance
systems [1, 2] ; to collect data on cases and exposed
persons [3, 4] ; and to provide information for those
at risk [5–8]. A range of methods has been used in-
cluding facsimile, email [4], the internet [3], mobile
phones and video links [9–12]. However, few of these
methods have been evaluated. We reviewed specimen
submission rates in order to evaluate the use of a
facsimile cascade to improve the identiﬁcation of
cases in an outbreak investigation.
In mid-September 2002, we identiﬁed several cases
of Q fever among employees of a cardboard manu-
facturing plant in the city of Newport, Gwent, UK
[13]. Home addresses of the cases were scattered over
a wide area. As part of the outbreak investigation,
we decided to instigate case searching for Q fever in
patients presenting to local primary-care physicians in
order to exclude the possibility that a larger outbreak
was occurring in the community. We used a well-
established facsimile cascade system, operated on be-
half of the public health department by a national
telephone service provider, to send a facsimile to all
primary-care practices in the area. Two facsimiles were
sent to all 106 primary-care practices (representing
360 primary-care physicians) in the Gwent locality,
covering an area of 600 square miles and a population
of over 560 000 people on 17 and 20 September 2002.
Physicians were asked to submit serum samples on
any patient meeting a clinical case deﬁnition of Q fever
and an association with the area where the outbreak
appeared to be occurring.
To assess whether primary-care physicians had re-
sponded to these facsimiles a centralized computer
database holding all laboratory records for the area
was interrogated. We identiﬁed all complement
ﬁxation (CF) tests for Coxiella burnetii requested by
primary-care physicians between 1 September 2001
and 31 October 2001 and between 1 September 2002
and 31 October 2002. Patients’ dates of birth, but not
their names, were used as personal identiﬁers. Where
more than one sample had been submitted on a
patient, only the ﬁrst sample submitted was used in
our analysis. The number of individuals tested in each
week was plotted using Microsoft Excel. We com-
pared the number of patients tested by primary-care
physicians on the corresponding weeks of September
and October 2001 and 2002. The paired Wilcoxon
signed rank test was used to assess statistical
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signiﬁcance. The null hypothesis tested was that there
was no statistically signiﬁcant diﬀerence between the
number of patients tested for Q fever in the target
population in each week between September and
October 2001 compared to the corresponding week in
September and October 2002. A second analysis
comparing the number of patients tested on each
corresponding day of the two time-frames was also
undertaken to ensure that summarizing the data by
week did not aﬀect the results.
The locality’s population did not change signiﬁ-
cantly between 2001 (563 542) and 2002 (567 315).
Direct comparisons could therefore be made between
the numbers of patients tested in these two years.
Primary-care physicians submitted CF tests for Q
fever on 69 individuals between 1 September 2001 and
31 October 2001 compared with 212 individuals
between 1 September 2002 and 31 October 2002 (see
Fig.). The graph demonstrates a bulge in the number
of patients tested in 2002 compared to a relatively
constant number of patients tested in 2001. The dif-
ference precedes the facsimile transmission but is most
apparent after it. The paired Wilcoxon signed rank
test for the diﬀerence in the proportion of the popu-
lation tested in 2001 and 2002 was P<0.001 both
when data were compared on a weekly and on a daily
basis. Data on the geographical pattern of samples
submitted was not available. Local laboratory staﬀ
indicated that they were not aware of a rise in samples
coming in from other surrounding areas during the
outbreak and that the rise in the number of samples
received by the laboratory did not reﬂect a general rise
in the number of CF tests for Q fever received between
2001 and 2002. The 212 CF tests submitted in 2002
included 185 samples with a titre off8, three samples
with a titre of 16, eight samples with a titre of 32, four
with a titre of 64, eight with a titre of 128, three with a
titre of 256, and one with a titre of 512.
One previously unrecognized case of Q fever was
identiﬁed as a result of samples submitted by primary-
care physicians. However, further investigation in-
dicated that this individual was not associated with
the main outbreak but represented a sporadic case of
Q fever and had been exposed to recognized risk fac-
tors for the disease elsewhere. We expected to identify
more previously unrecognized cases than this as a
consequence of our case searching. There are several
reasons why the number of new cases identiﬁed was so
small. First, this outbreak was particularly localized
and the at-risk group was concurrently identiﬁed by a
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Fig. Number of patients with Q fever antibody tests, submitted by primary-care physicians in Gwent in 2001 and 2002 and
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cohort study of those working or attending a speciﬁed
factory premises. Second, CF tests were used to screen
the samples submitted rather than newer, more sen-
sitive and speciﬁc immunoﬂuorescent tests, which
might have identiﬁed a larger number of cases in the
general population.
The facsimiles sent to primary-care physicians ap-
pear to have contributed to a prompt and statistically
signiﬁcant increase in the number of requests for Q
fever serology. Test results suggest that there was no
wider outbreak of Q fever, since despite the large
number of community samples submitted around the
time of the outbreak, only one new case of Q fever was
identiﬁed.
There are a number of weaknesses and potential
biases in the study that need to be considered. Factors
other than receiving a facsimile would have con-
tributed to the increase in serology requests received
in September 2002. For example, local press state-
ments (although these did not occur until after the
ﬁrst facsimile was sent), local peer-group networks
and contacts with hospital staﬀ would have increased
awareness of the outbreak. Increased awareness of the
outbreak and subsequent increased self-presentation
of patients concerned about the possibility of Q fever
may also have been a factor. A few GPs were phoned
with a request to take blood samples of speciﬁc
patients prior to the sending out of the facsimiles. Use
of date of birth to remove duplicates, undertaken to
maintain patient conﬁdentiality, may have removed a
few individuals who coincidentally had the same date
of birth.
Anecdotal evidence from the laboratory suggests
that although local GPs occasionally ask for an
atypical pneumonia screen, including Q fever serol-
ogy, they very rarely name Q fever serology directly
on the request form. In contrast, in September 2002
a large number of the primary-care samples shown
in the Figure directly requested Q fever serology.
This provides indirect evidence to suggest that the
facsimiles were linked to the requests for Q fever
serology.
Doctors receive large quantities of correspondence
[14] and vary in the quantity they read [15, 16]. We
were not certain that our facsimiles would be read or
acted upon. However, this study suggests that at least
some primary-care physicians read and acted upon
the facsimile cascade sent out as part of this outbreak
investigation. It is not clear what proportion of the
360 primary-care physicians saw patients who met
the case deﬁnition for Q fever but were not tested.
A survey of the physicians might have produced
additional useful information.
A number of previous evaluations of facsimile
were identiﬁed by searching Medline 1966 to week
47, 2003 and EMBASE 1980 to week 47, 2003 for
facsimile.mp limited to ‘human’, English language
articles. In most of the 151 references identiﬁed the
use of facsimile was incidental to the focus of the
paper and the outcomes measured did not relate to
the use of facsimile. Eight evaluations of facsimile
transmission were identiﬁed of which seven suggested
some beneﬁt. One was in a communicable disease
context [2]. Three papers evaluated ‘one to one’
transmission of clinical information by facsimile
[17–19]. Two papers evaluated ‘many to one’ trans-
mission by facsimile from patients or peripheral
health-care workers back to a central hub [20, 21].
Three papers evaluated ‘one to many’ transmission
(facsimile cascade) from a centre to peripheral sites
[2, 22, 23]. One study provided limited evidence
for the use of facsimile cascade to disseminate infor-
mation and intensify surveillance during a period
when there was increased risk of a disease outbreak.
In 1994 a facsimile cascade was used to disseminate
information to a wide range of public health oﬃcials
by the Centers for Disease Control (CDC; Atlanta,
GA, USA) in response to a reported epidemic of
plague in India [2]. The CDC Fax Information Service
subsequently sent out a further 5589 documents pro-
viding information about plague using an automated
fax back system to handle requests for further in-
formation. This resulted in the identiﬁcation of 13
travellers who were potentially at risk of incubating
plague although none of these cases proved positive.
A high percentage of primary-care physicians have
access to a facsimile machine and there is some
evidence that they have a preference for this method
of communication [24].
In conclusion, this study provides some evidence
that sending a facsimile cascade to primary-care
physicians, may assist in the identiﬁcation of cases
during an outbreak investigation and may provide the
basis for the design of future studies investigating
the usefulness of facsimile for communicating with
primary-care physicians.
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Abstract 
The frequency and range of long-term
sequelae following acute Q fever infection
remains controversial. This study aimed to
assess a range of potential psychological and
physical sequelae in a follow up study of a large
outbreak of Q fever that occurred in Newport,
Wales, in 2002. A nested case control study was
undertaken six years after a point source out-
break of Q fever. We invited a cohort of 211 fac-
tory workers exposed to a point source of Q
fever in 2002 to attend a follow up clinic in
2008. Cases, defined as those who had clinical
symptoms and serological evidence of acute Q
fever in 2002, were compared to controls, who
worked in the same factory but were serologi-
cally negative at the time of the outbreak. At
the follow up clinic blood was taken for
Coxiella burnetii microimmunofluorescence
and questionnaires were completed including
the PHQ-9, Chalder Fatigue scale, and General
Health Questionnaire. Results were obtained
for 32 cases and 13 controls. Chalder Fatigue
scores were significantly raised in the cases
(independent samples t-test: P=0.047). PHQ-9
and GHQ scores were not significantly raised
in cases. However, post hoc cross sectional
analysis indicated a relationship between
Phase 2 IgG at follow up in 2008 and Chalder
Fatigue scores (P=0.004) and PHQ-9 scores
(0.049). A longitudinal association was
demonstrated between acute Q fever infection
and chronic fatigue six years later. In cross-
sectional analysis a previously unreported
relationship between depression scores (PHQ-
9) and positive Q fever serology was also iden-
tified.
Introduction
A number of follow up studies of patients
with acute Q fever1-8 and serological examina-
tion of patients presenting with Chronic
Fatigue Syndrome,9 have indicated that Q fever
may be associated with chronic fatigue. A rela-
tionship between previous Q fever and symp-
toms of depression can also be postulated.10
The underlying aetiology of the association
between Q fever and chronic fatigue remains
unclear. The extent to which chronic symptoms
are influenced by the strain of C. burnetii, psy-
chosocial factors, immunological or genetic
factors is also uncertain.11,12 The possibility of
long term effects following acute infection is
supported by evidence that the aetiological
organism can be detected in a proportion of
patients by PCR many years later.13-15 It is still
unclear whether patients that have long stand-
ing chronic fatigue after acute Q fever gain
any benefit from antibiotic treatment.16,17
A point source outbreak of Q fever occurred
in a cardboard manufacturing plant in
Newport, South Wales, in 2002.18 This out-
break was one of the largest to have occurred
in the UK. During the initial outbreak, the
exposed cohort was identified and a nested
case control study was undertaken to assess
the difference in exposure between cases and
controls to a range of potential sources of the
outbreak. The cohort of factory workers,
including affected and unaffected individuals
provided the opportunity for a follow up study,
which was conducted six years later in 2008.
The serological findings of the follow up study
have been published.19 The current paper com-
pares the symptoms of the original cases and
controls in a follow up study. The aim of the
study was to assess the hypotheses that i)
chronic fatigue, ii) depression and iii) reduced
physical function were more common in those
who had acute Q fever in 2002 compared to
those individuals in the cohort who worked in
the same factory but did not demonstrate evi-
dence of infection at the time of the outbreak.
Materials and Methods
From the initial cohort of 226 individuals
who worked in the factory in 2002, all 131 sero-
logically positive cases were invited to take
part in the follow up study in 2008, as were a
random sample of 80 of the 95 serologically
negative individuals. A written invitation to
participate, including a leaflet outlining the
proposed study, was therefore sent to 211
potential participants.
Those individuals who agreed to take part in
the study were invited to a clinic where blood
was taken for microimmunofluorescence test-
ing for presence of Coxiella burnetii Phase 2
IgG and IgM antibodies and Phase 1 IgG and
IgA antibodies. The microimmunofluorescence
assays used antigen from Patient strain Lane -
ST12 group. The blood samples were analysed
by the standard reference laboratory in the UK,
the Special Pathogens Reference Unit, HPA
Centre for Emergency Preparedness and
Response, Porton Down, Salisbury, SP4 0JG.
Questionnaires including the PHQ-920 which
assesses the severity of symptoms of depres-
sion, the 11 item version of the Chalder
Fatigue scale,21 and the General Health
Questionnaire (GHQ) which assesses physical
health22 were completed at the clinic. The
questionnaire included two new single item
tests for fatigue. Firstly, If you are tired at the
moment how long has this lasted? Response
options were not reported being tired, less than
one week, one week to 3 months, 3 to 6 months,
6 months or more. For analysis the results were
dichotomised into those who had fatigue for
six months or more and those who had fatigue
for less than six months. Secondly, the ques-
tionnaire asked, What percent of the time do
you feel tired? Response options were 0%, 25%,
50%, 75%, or 100% of the time. Responses
were dichotomised into those who reported
being tired less than 50% of the time and 50%
of the time or more.
The PHQ-9 is a self-administered subset of
the PRIME-MD diagnostic instrument for com-
mon mental disorders. It is a widely used and
well validated measure of depression based on
nine questions that start with the stem, Over
the last 2 weeks, how often have you been both-
ered by any of the following problems? Answers
range from 0 (not at all) to 3 (nearly every
day). The Chalder Fatigue scale used in this
analysis contains 11 questions covering the
physical and mental symptoms of fatigue
including, tiredness, need to rest, feeling
drowsy, problems starting things, and difficulty
concentrating. The General Health Question-
naire is a broad ranging and widely used meas-
ure of physical health. The two other questions
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on fatigue duration and percent of time affect-
ed by fatigue were not previously validated
questions.
Questionnaire data was analysed using
Microsoft Excel® and SPSS®. In view of the rel-
atively small sample sizes, the non-parametric
Mann-Whitney U test for two independent
samples was used to compare variables.
Variables were also dichotomised and com-
pared using the chi-square test. Fishers’ exact
test was used where where one cell had an
expected count of less than five.
Ethical approval for the study was granted by
the South East Wales Research Ethics
Committee Panel C.Longitudinal and cross sectionalanalyses
The data was analysed as a nested case con-
trol study, based on the status of participants
in 2002 as cases or controls. In 2002 cases
were defined as those members of the exposed
cohort who had clinical symptoms of acute Q
fever infection and serological evidence of
infection as demonstrated by a Phase 2 IgM
≥80, or a fourfold rise on sequential Comple-
ment Fixation Tests (CFT). Non-cases were
defined as those who had no symptoms of
acute Q fever infection and no serological evi-
dence of infection with no IgM, no CFT and no
Phase 1 or 2 IgG. Three patients who did not
unambiguously meet criteria as cases or con-
trols were excluded from analysis. They had
uncertain serology defined as no IgM, no four-
fold rise in CFT but CFT ≥ 8 or Phase 1 or 2 IgG
> 160. Two of the three individuals with uncer-
tain serology had symptoms; the third individ-
ual did not. These three individuals were
excluded from all the analysis presented in this
paper.
A post hoc cross sectional analysis of the
cohort was also undertaken, assessing the
relationship between current clinical symp-
toms at the time of the clinic in 2008 and
Phase 2 IgG blood results from samples taken
at the same time. Phase 2 IgG titres were
recorded as 0, 320, 640, 1280, or 2560. Scores
for clinical symptoms were dichotomised as
follows: Chalder Fatigue (0-3, 4-11); PHQ-9
scores (dichotomised at the median: 0-3, 4-9);
duration of tiredness (less than 6 months, 6
months or more); percent of time participants
felt tired (less than 50% of the time, 50% of the
time of more); and GHQ scores (dichotomised
at the median: 0-2, 3-12).
Results
Results for analysis were available for 45
individuals out of a total of 52 individuals who
attended the follow up clinic. This represented
24.4% of cases invited to the clinic (32/131)
and 16.3% of the controls invited to the follow
up clinic (13/80). The characteristics of the
cohort used for the nested case control study
are shown in Table 1. Both groups were pre-
dominantly male, reflecting the population in
the factory where the outbreak occurred. The
mean age of cases was 50.18 yrs (SD 9.85,
range 27-64 yrs) and the mean age of controls
was 53.57 yrs (SD 8.86, range 36-68 yrs).
Educational attainment was similar in both
groups: 37.5% (12/32) of cases and 38.5%
(5/13) of controls had remained in education
after the minimum school leaving age.
Nested case control study
A table showing the relationship between
status in 2002 and symptoms in 2008 is provid-
ed in Table 2. Raised Chalder Fatigue scores
were more common in cases (P=0.047). The
single questions analysing symptoms of tired-
ness for 6 months or more or tiredness for 50%
of the time or more were not statistically signif-
icantly associated with being a case. Neither
were PHQ-9 scores (P=0.189) or GHQ scores
(P=0.743).Cross sectional analysis
A second post hoc analysis of the cohort was
Article
Table 1. Summary of cases and controls (bases on status in 2002) by gender.
Status Total
Case Control
Gender
Female 7 1 8
Male 28 13 44
Total 35 14 52
Table 2. Relationship between status as defined in 2002 (cases and controls) and clinical
symptoms in 2008.
Comparison N Cases Controls Fisher’s
Exact
test P
Chalder fatigue score 0-3 4-11 0-3 4-11
45 13 19 10 3 0.047
Tired for 6 months or more < 6 months ≥ 6 months < 6 months ≥ 6 months
39 11 17 8 3 0.082
Tired for 50% of the time or more 0-50% 50-100% 0-50% 50-100%
40 7 21 6 6 0.154
PHQ-9 1-3 4-9 1-3 4-9
45 14 18 9 4 0.189
GHQ 0-2 3-12 0-2 3-12
49 22 13 10 4 0.743
Table 3. Relationship between Phase 2 IgG in 2008 and symptoms measured at the same
time.
Comparison N Mean  rank Sum of Mann-
Ranks whitney U
Phase 2 IgG Chalder Fatigue score (0-3) 23 17.91 412.00 136.000
Chalder Fatigue score (4-11) 22 28.32 623.00 P = 0.004
Total 45
Phase 2 IgG Tired for 6 months or more 19 16.45 312.50 122.500
Not tired for 6 months or more 20 23.38 467.50 P = 0.037
Total 39
Phase 2 IgG Tired less than 50% of the time 13 14.69 191.00 100.000
Tired 50% of the time or more 27 23.30 629.00 P = 0.017
Total 40
Phase 2 IgG PHQ-9 score (0-3) 23 19.52 449.00 173.000
PHP-9 score (4 – 9) 22 26.64 586.00 P = 0.049
Total 45
Phase 2 IgG GHQ score (0-2) 32 23.86 763.50 235.500
GHQ score (3-12) 17 27.15 461.50 P = 0.406
49
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undertaken to assess whether symptoms
recorded at the follow up clinic in 2008 were
associated with Phase 2 IgG results taken at
the same time (Table 3). There was a clear
relationship between higher C. burnetii Phase
2 IgG and raised Chalder Fatigue score (P=
0.004), tiredness for 6 months or more (P=
0.037), tiredness for 50% of the time or more
(P=0.012), and raised PHQ-9 score (0.049),
but not GHQ score (P=0.406).
Similarly, dichotomising C. burnetii Phase 2
IgG scores to 0-640 and 1280-2560 and assess-
ing the relationship with symptoms using the
chi-square test indicated a clear relationship
to clinical symptoms of fatigue: Chalder
Fatigue score (chi-square 8.049; P=0.005),
tiredness for 6 months or more (chi-square
4.311; P=0.038), tiredness for 50% of the time
or more (chi-square 6.686; P=0.01).
Relationships with PHQ-9 score (chi-square
2.702; P=0.1), and GHQ score (chi-square
0.634; P=0.426) were not statistically signifi-
cant. Four of the fourteen control subjects
(based on their status in 2002) had C. burnetii
Phase 2 IgG titres of 320 for Q fever at follow
up in 2008.
Discussion
Chalder Fatigue scores were significantly
raised six years later in those individuals who
were diagnosed with acute Q fever at the time
of the outbreak. In contrast, general health, as
measured by the GHQ, was not significantly
different from controls drawn from the same
cohort of individuals who worked in the same
factory at the time of the outbreak. There is a
statistically significant cross-sectional rela-
tionship (P=0.049) at the time of follow up
between raised serology by microimmunofluo-
rescence and both Chalder Fatigue scores and
depression as measured by the PHQ-9.
Symptoms of fatigue and depression can over-
lap and can be difficult to differentiate.
However, as these results were derived from
the cohort of workers exposed to Q fever in the
initial outbreak in 2002, there is some evi-
dence to suggest that depression may be a
associated with previous Q fever infection.
This finding will need verified by future stud-
ies. An unexpectedly large proportion of the
controls (28.6%) were serologically positive at
follow up. This figure is much higher than the
sero-prevalence of Q fever in the UK popula-
tion.23 The positive Q fever serology may repre-
sent late sero-conversion due to exposure at
the time of the outbreak, later exposure to Q
fever, or false positive results. 
The main strength of this study was that it
used validated questionnaires to assess symp-
toms associated with the long term sequelae of
Q fever subsequent to a point source outbreak.
The study was also strengthened by the fact
that controls were drawn from the same envi-
ronment as cases. However, some controls may
indeed have been unidentified asymptomatic
cases and a separate population of control sub-
jects would have strengthened this study fur-
ther. The potential inclusion of some cases in
the control group would reduce the power of
the study to detect an effect and should, there-
fore, not have introduced bias in favour of our
findings.
The sample size in this study is small and
the response rate is relatively low. Participants
were aware whether or not they had been diag-
nosed as having acute Q fever in initial out-
break and this may have introduced some
reporting bias when completing the follow up
questionnaires. Potential problems in inter-
preting serological results and defining inter-
national standards for acute, past and chronic
infection have been considered in a previous
report.19
It would have been helpful to have informa-
tion on other blood borne infections that could
have contributed to chronic fatigue. However,
we have no reason to suspect that the preva-
lence of such infections would be different in
cases and controls. Consequently, this issue
should not have materially affected our find-
ings. It would have been interesting to assess
whether there was a relationship between the
nature of the work undertaken by each partici-
pant in the study and their level of fatigue. In
particular, whether there was a relationship
between the symptoms of chronic fatigue and
the level of physical exertion undertaken on a
day to day basis or the shift pattern worked by
the individuals concerned. It would also have
been useful to compare the frequency and
duration of sick leave in cases and controls.
Unfortunately, none of this information was
collected. One patient from this cohort devel-
oped Q fever endocarditis and was treated with
antibiotics. However, it is unclear whether or
not chronic fatigue after Q fever infection
should be treated with antibiotics. Raised Q
fever serology is more common in patients
with Chronic Fatigue Syndrome than in the
background population.9 Small studies have
shown that some patients with chronic fatigue
and raised Q fever serology respond to antibi-
otic treatment.16,24 However, high antibody lev-
els may indicate high responder status rather
than the actual presence of the microorgan-
ism. This study points up the desirability of a
trial of antibiotics in patients with post q fever
chronic fatigue.
Conclusions
This study has demonstrated that chronic
fatigue was more common six years later in
patients who were infected with Q fever during
an outbreak. The study has also raised the pos-
sibility of a relationship between raised C. bur-
netii Phase 2 IgG and symptoms of chronic
fatigue and depression. 
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Chronic Q Fever: Different Serological Results in
3 Countries—Results of a Follow-up Study 6
Years After a Point Source Outbreak
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Background. Acute and chronic Q fever/Coxiella burnetii infection is diagnosed principally by serology. The
management of patients who have serological evidence of chronic Q fever but no other manifestation of chronic
infection is challenging.
Methods. This paper describes a follow-up study of individuals 6 years after a point source outbreak. The study
compares serological and polymerase chain reaction (PCR) results between 3 international reference laboratories in
a well-defined cohort of Q fever patients.
Results. Concordance in microimmunofluorescence result interpretation from the 3 centers was only 35%.
Australian and UK results had the greatest concordance and French and UK results the lowest. Serological testing
revealed no chronic serological profiles when tested in either France or Australia but 10 when tested in the UK.
Serological results from a patient with treated Q fever endocarditis suggested treated (France), chronic (UK), and
borderline chronic (Australia) infection. PCR results on blood were universally negative.
Conclusions. This study has shown that the results from Q fever micro-immunofluorescence vary according to the
center in which they are carried out. This has implications for the interpretation of such tests, raises questions regarding
the validity of using serological criteria alone as a means of diagnosing chronic Q fever, and affects the interpretation of
epidemiological studies. We recommend that all results are interpreted according to the clinical picture and particular
caution is applied in the interpretation of chronic serological profiles. In order to further our understanding of Q fever
infection we propose that an international standard of Q fever serological investigation be developed.
Q fever is an infection caused by an obligate intracellular
bacterium Coxiella burnetii. It causes acute Q fever, the
most frequent manifestations of which are a self-limiting
febrile illness, hepatitis, or pneumonia. In some in-
stances the infection is entirely asymptomatic.
The presentation of chronic Q fever is heterogeneous.
The most common manifestation is Q fever endocarditis
in patients with preexisting valvular heart disease [1].
Difficulties in diagnosing chronic Q fever infection
clinically have led to the development of diagnostic se-
rological criteria. These criteria are based on studies that
mostly compare acute Q fever patients with those that
have Q fever endocarditis. The most commonly quoted
criteria [2], developed in France, are used on a world-
wide basis to interpret Q fever serology.
The management of patients who only partially meet
the diagnostic criteria for chronic Q fever is challenging.
Although not widely published in the literature, this
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phenomenon—patients with raised Coxiella burnetii antibody
titres, no other clinical features of chronic infection and who do
not fulfill modified Dukes criteria for endocarditis—is well rec-
ognized [3]. PCR has been proposed as a means of distinguishing
those patients in this category that have Q fever endocarditis or
vascular infection [4]. The significance of a negative PCR result
has not been evaluated prospectively nor has PCR been evaluated
on a cohort of patients with raised Q fever antibody levels (UK
testing) but no other signs of chronic infection.
This paper describes a follow-up study of individuals 6 years
after a point source outbreak in a cardboard box manufacturing
plant in Newport, Gwent, 2002 [5]. The original outbreak
consisted of 106 cases of acute Q fever (84% symptomatic) from
a factory of 250 employees [5]. All infected individuals were
invited to a follow-up clinic. The clinic identified 1 case of en-
docarditis [6] (by modified Dukes criteria) and 38 individuals
with phase 1 IgG titres .800, consistent with chronic Q fever,
but with no other manifestations of infection. They were afe-
brile, with normal C reactive protein, erythrocyte sedimentation
rate (ESR), and white cell counts and did not have valve lesions
diagnostic of endocarditis. The optimal management of these
individuals is uncertain. This study examines the relationship
between serological results and clinical features and compares
serological and PCR results between 3 international reference
laboratories in a well-defined cohort of Q fever patients.
Aims
The aims of this study were as follows:
1. To describe the spectrum of long-term consequences of Q
fever infection in the South Wales outbreak population 6 years
after exposure to point source
2. To assess the relationship between clinical symptoms and
serological results 6 years after initial infection in 4 subgroups: (i)
those with raised phase 1 IgG antibodies to Coxiella burnetii,
(consistent with chronic Q fever), (ii) individuals with apparent
recovery from Coxiella burnetii (as defined by low or absent
phase 1 IgG antibodies), (iii) individuals who were potentially
exposed but apparently uninfected, and (iv) 1 patient with
proven Q fever endocarditis who had completed treatment.
3. To compare serological tests undertaken by 3
international reference laboratories in a well-defined cohort
of Q fever patients.
4. To compare the use of PCR with serological tests in the
diagnosis of chronic Q fever and examine its’ role in
differentiating patients into groups that have (i) active
infection, (ii) those that have recovered clinically, and (iii)
those who have quiescent infection.
5. To determine whether Q fever infection results in chronic
persistence of the organism in the blood, as defined by PCR.
METHODS
Individuals from the exposed cohort were categorized into 4
groups, differentiated on the basis of serological tests for Q fever
antibodies (UK reference laboratory results, Table 1).
Informed consent was taken prior to entry into the study
and ethical approval was granted by South East Wales Re-
search Ethics Committee Panel C. Eighty of the 95 uninfected
controls were selected using a random number generator
(group 3).
Blood was taken for a full blood count, urea and electrolytes,
liver function tests, CRP, ESR, rheumatoid factor, thyroid
function tests, thyroid peroxidase antibodies, immunoglobulin,
Coxiella burnetii microimmunofluorescence and PCR. Serum
samples were sent to 3 separate reference laboratories in the UK
(Special Pathogens Reference Unit SPRU), France (Unite des
Rickettsies, Marseille), and Australia (Australian Rickettsial
Table 1. Criteria, Intended Recruitment, and Attendance of Different Groups Defined for the Follow-up Study in 2008
Group Criteria Number of potential recruitable individuals Invited to take part Attended
Group 1 Infected with phase 1 IgG titres .800 at any time 39 39 18 (46%)
Group 2 Infected with phase 1 IgG titres consistently ,800 91 91 19 (21%)
Group 3 Serologically negative 95 80 14 (17.5%)
Group 4 Q fever endocarditis—treated 1 1 1 (100%)
Total 226 211 52 (25%)
Table 2. Information on MIF and PCR Tests
Reference laboratory
MIF antigen
PCR target (reference)Phase 2 Phase 1
ARRL, Australia Nine mile (clone 4) Henzerling strain Com 1 and IS1111a [7]
SPRU, UK Patient strain ‘‘Lane’’— ST12 group Patient strain ‘‘Lane’’—ST12 group IS1111a, COM1, and 16sRNA [8]
Unite des Rickettsies,
Marseille, France
Nine mile (ATCC VR615) (2) Nine mile (ATCC VR615) (2) IS1111a x 2 targets [4]
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Reference Laboratory) for microimmunofluorescence and PCR
tests (in house assays) (Table 2) [2, 4, 7–9]. Participants were
asked to complete a questionnaire containing a number of val-
idated health measures (not reported in this paper).
A serological status was assigned to each individual based on
the results from each center using the most commonly accepted
interpretation rules (Table 3) [2]. A ‘‘borderline’’ category was
added as there is uncertainty in managing patients with a phase 1
immunoglobulin G (IgG) of between 400 and 800, as Q fever
endocarditis has been recognized in at least 1 patient with
a phase 1 IgG , 800. It is recognized that these thresholds are
not universally adopted. For example, in France a serological
titre of 800 would be considered borderline (D. Raoult, oral
communication, 2010).
RESULTS
Of 212 individuals invited to take part in the study, 52 at-
tended for blood testing (see Table 1) and 50 completed
questionnaires.
The results from the 3 centers interpreted using recognized
criteria [2] are shown in Table 4. Table 5 shows the results
according to original status groups 1–4. The concordance be-
tween the test results from the 3 laboratories was 35% (18/52)
overall, 35% (18/52) France cf UK, 42% (22/52) France cf
Australia, and 71% (37/52) Australia cf UK (Table 6).
Concordance was greatest between Australian and UK labo-
ratories and lowest between French and UK laboratories.
Discordant Results
Discordant results are shown in Table 7 (18 out of 52 results,
35%).
Four participants had a different status assigned by all 3
centers (Table 7, bold type, nos. 2, 3, 4, 35).
If borderline is considered as a separate category there are
a further 6 participants with different serological results in each
center (Table 7, italics, nos. 1, 5, 6, 12, 13, 14).
Eighteen participants had the same serological status assigned
by all 3 centers, 10 negative results, 8 past infections (although 3
of these results from the UK gave a borderline chronic sero-
logical profile, nos. 15, 16, 17).
Chronic/Borderline Serological Profile
A chronic serological profile was present in 10 individuals when
tested in the UK (Table 7) but not in any tests performed in
either France or Australia. Eight individuals had borderline re-
sults for chronic Q fever when tested in the UK. There were 3
borderline results from Australia (Table 6, nos. 5, 6, 15) and one
borderline result from France (Table 6, no. 1).
Follow-Up Results of Serologically Negative Participants
(Group 3)
Of the 12 participants from group 3 (asymptomatic and sero-
logically negative at the time of the outbreak), 4 were serologi-
cally positive by the UK reference laboratory test, 3 by the
Australian, none by the French, and 5 by any of the 3 labs (table
5). It is not possible to determine whether this represents late
seroconversion, subsequent infection, or false positive serolog-
ical results. The rate of seroconversion, 5 of 12 cases in 6 years, is
high for a background rate of new infections, however.
Patient With Treated Endocarditis
One patient was diagnosed with endocarditis in March 2004 [6]
and treated for 22 months with doxycycline and hydroxy-
chloroquine. She was asymptomatic prior to treatment, and so
treatment response was judged by a fall in her C-reactive protein
(CRP) and serological titres (when tested in France). Her results
from this study would suggest past/treated infection (France,
Phase 1 IgG 50), chronic infection (UK, Phase 1 IgG .1280),
and borderline chronic (Australia, Phase 1 IgG 400). The patient
stopped treatment in July 2006 but remains under regular fol-
low-up. Since stopping treatment, there has been no increase in
her CRP and no further deterioration in her valve function.
PCR Results
PCR results on blood were universally negative in this study.
Biochemical Blood Test Results
The majority of blood results were within normal limits. There
are no results from routine blood tests that suggest those pa-
tients with a chronic serological profile have ongoing infection/
inflammation greater than those who have evidence of past in-
fection serologically or those who have been consistently sero-
negative. Three people had mildly elevated CRP. None of these
Table 4. Serological Status According to Testing Center [2]
France UK Australia
Negative 34 11 17
Past 18 (1) 29 (7) 32 (2)
Chronic 0 9 0
Acute 0 3 3
Total 52 52 52
NOTE. Figures in brackets are ‘‘borderline chronic’’ serological results—ie,
phase 1 IgG within 1 serial dilution of being >800 (400 or 640).
Table 3. Q Fever Infection Definitions Devised by Dupont et al [2]
With a Borderline Category Added for Results Within One Serial
Dilution of a Chronic Definition
Status Serological criteria
Chronic Phase 1 IgG > 800 or Phase 1 IgA>25
Past Phase 2 IgG detected and Phase 1 IgG ,800
Negative No antibody detected
Acute Phase 2 IgM > 50
Borderline Phase 1 IgG > 400 and , 800
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had a chronic serological profile, and all had serological profiles
that were either negative or suggestive of past infection (UK 3/29
past infection, 0/11 negative, France 1/18 past, 2/34 negative,
Australia 2/32 past, 1/17 Negative).
DISCUSSION
The main finding of this study is the discrepancy between se-
rological tests from different reference laboratories and the
consequent challenges that this presents in the interpretation of
serological results.
The clinical diagnosis of chronic Q fever infection is chal-
lenging. The presentation is heterogeneous and typical markers of
infection frequently absent. Q fever endocarditis, the commonest
manifestation of chronic Q fever, is a slow indolent disease, and
endocarditis is often only diagnosed after significant valvular
damage has occurred [10]. Chronic Q fever endocarditis can be
present in individuals who are afebrile [6, 11, 12], have a normal
ESR [12, 13], and normal routine haematological studies [11].
Chronic Q fever endocarditis can be entirely asymptomatic [6]
and can be both clinically and histologically silent [11–14].
A study by Raoult et al [15] has demonstrated that Q fever
infection of heart valves does not produce the typical histological
findings of endocarditis. In that study, valves removed because
of infection with Coxiella burnetii resembled valves removed
because of degenerative valve disease in almost every regard. The
presence of small vegetations and focal inflammatory changes in
the infected valves were the only distinguishing features. These
changes however were subtle and could be easily overlooked by
routine histological examination. In addition, 3 individuals had
no obvious infection on histology, no vegetations, and only
a slight inflammatory reaction. These findings in part explain
why even transoesophageal echocardiograms perform so poorly
in the diagnosis of Q fever endocarditis [1]. The long-term se-
quelae of these indolent infections has never been prospectively
evaluated, nor has the impact of treatment of these individuals
been assessed. A cohort study carried out by Swiss investigators,
however, has suggested that the long-term (12 year) risk of
endocarditis in a group of individuals acutely infected with
Coxiella burnetii is no different to a noninfected control pop-
ulation [16]. Equally, follow-up of patients with echocardio-
graphic evidence of valvulopathy has suggested the short-term
risk of endocarditis is low [17].
Because chronic Q fever infection is extremely difficult to di-
agnose, the optimal management of individuals with raised titres
but no other evidence of ongoing infection is uncertain. The
management is further complicated by the duration and potential
toxicity of the recommended treatment regimen, doxycycline and
hydroxychloroquine for a minimum of 18 months.
Although local serological thresholds should ideally be de-
veloped (using Bayes theorem) and interpreted in the light of
clinical information, in clinical practice published criteria are
often used in isolation to interpret serological results. A variety
of serological criteria to diagnose chronic Q fever infection have
been published [2, 18–22] resulting in the following (sometimes
contradictory) recommendations:
d Phase 1 IgG. Phase 2 IgG, Elevated Phase 1 IgG or Phase 1
IgA [19].
d Phase 1 IgA > 320 and CFT . 128 [18].
d Phase 1 IgG . 800, Phase 1 IgA not contributory [2].
d Phase 1 IgG . Phase 2 IgG 1 Phase 1 IgA . Phase 2 IgA
[20].
d Phase 1 . Phase 2 [21].
d High Phase 1 IgG and Phase 1 IgA [22].
In these studies, the phase 1 IgG ranged from 640 to
2,097,152. In the majority of these studies, serological results of
patients with chronic Q fever endocarditis were compared with
those from acute Q fever patients. However, a proportion of
people will develop phase 1 antibodies after Q fever infection: in
3 studies the proportion of patients who did so was 15 of 51
[23], 11 of 20 [20], and 3 of 3 [22]. These phase 1 titres are not
necessarily associated with chronic illness, and it has been
Table 5.
a) Results on Patients From Group 1; Infected With Phase 1 IgG
Titre ‡ 800 at Any Stage N 5 18
Negative Acute Past Chronic
UK 0 0 11 (4) 7
France 5 0 13 (1) 0
Australia 0 2 16 (1) 0
b) Results on Patients From Group 2; Infected With Phase
1 IgG Titre Consistently < 800 N 5 19
Negative Acute Past Chronic
UK 1 2 14 (3) 2
France 15 0 4 0
Australia 6 0 13 0
c) Results on Patients From Group 3; Serologically Negative
N 5 14
Negative Acute Past Chronic
UK 10 0 4 0
France 14 0 0 0
Australia 11 1 2 0
d) Results on Patient From Group 4; Q Fever
Endocarditis—Treated N 5 1
Phase 1 IgG Interpretation
UK .1280 Ongoing treatment required
France 50 Cured
Australia 400 Ongoing treatment required
NOTE. Figures in brackets are ‘‘borderline chronic’’ serological results—ie,
phase 1 IgG within 1 serial dilution of being >800 (400 or 640).
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proposed that development of phase 1 IgG antibodies is part of
the normal response to Q fever infection [24].
In one study, cases of Q fever endocarditis were compared
with cases of acute Q fever that had been followed up for be-
tween 8 and 88 months [18]. Phase 1 IgG was present in all of
the control subjects and was .800 in 2 of them. Two also had
phase 1 IgA of 320 and CFT of 64.
The Duke criteria have been modified to permit improved
diagnosis of Q fever endocarditis, and phase 1 IgG antibody titre
> 800 to Coxiella burnetii is now considered a major criterion for
the diagnosis of endocarditis [25, 26]. In many countries the
diagnosis of chronic Q fever will be suspected if an immunoflu-
orescence phase 1 IgG antibody> 800 is detected, and physicians
may consider starting treatment based on serological results alone.
The optimal management of patients with raised phase 1 IgG
levels but no other markers of chronic infection, however, is not
clear [3]. It has been proposed that PCR on blood of patients
with phase 1 IgG serological titres ,1:25600 can identify those
with active endovascular infection [4]. In that study, overall
sensitivity of PCR was 27% (13/48), 39.4% (13/33) in patients
with titres ,1:25600, 64% (7/11) in those samples tested pro-
spectively, and 100% (7/7) in patients with titres ,1:25600
tested prospectively [4]. One hundred patients with endocarditis
caused by other organisms were used as a control group. The
significance of a negative PCR result has not been evaluated
prospectively, nor has PCR been evaluated on a cohort of pa-
tients with raised Q fever antibody levels (UK testing) but no
other signs of chronic infection.
The follow-up of patients following Q fever infection is
further complicated by the finding that 88% of individuals
from a previous UK outbreak [27] had bone marrow samples
that were positive by PCR for Q fever 12 years after their
acute infection and regardless of their clinical state at the
time the samples were taken [9]. Some of these patients had
ongoing fatigue, but others had made a complete clinical
recovery. All attempts at culture of the bone marrow were
unsuccessful [9] including PCR positive marrow/peripheral
blood cell homogenates from 10 patients that were in-
oculated into SCID mice [28]. Although no coxiella were
isolated, coxiella antigen-LPS complexes were detected by
immunofluorescence in SCID mice spleens. The authors
propose that noninfective, nonbiodegradable antigen-LPS
complexes persist in the host, and these can provoke
aberrant humoral and cell mediated immunity responses
[28, 29].
This study has shown that there is discordance in the sero-
logical results generated by 3 reference laboratories in UK,
France, and Australia. A similar disparity between American and
French test results has been found in the United States [3].
It is not possible to determine the sensitivity or specificity
of the results from each center as Q fever is frequently
Table 6. Concordance of Tests Results Across the 3 Testing
Centers
Comparison of
centers
Concordance in
result interpretation Percentage
All 3 centers 18/52 35%
France cf UK 18/52 35%
France cf Australia 22/52 42%
Australia cf UK 37/52 71%
Table 7. Discordant Serological Status Attributed by Different
Testing Centers
Number
Serological status
UK France Australia
1 Chronic Borderline Past
2 Chronic Negative Past
3 Chronic Past Acute
4 Chronic Past Acute
5 Chronic Past Borderline
6 Chronic Past Borderline
7 Chronic Past Past
8 Chronic Past Past
9 Chronic Past Past
10 Chronic Past Past
11 Borderline Negative Negative
12 Borderline Negative Past
13 Borderline Negative Past
14 Borderline Negative Past
15 Borderline Past Borderline
16 Borderline Past Past
17 Borderline Past Past
18 Past Negative Negative
19 Past Negative Negative
20 Past Negative Negative
21 Past Negative Negative
22 Past Negative Negative
23 Past Negative Past
24 Past Negative Past
25 Past Negative Past
26 Past Negative Negative
27 Past Negative Past
28 Past Negative Past
29 Past Negative Past
30 Past Negative Past
31 Past Negative Past
32 Past Negative Past
33 Past Negative Past
34 Past Negative Past
35 Acute Negative Past
36 Acute Past Past
37 Negative Negative Acute
NOTE. Number 5 5 Patient diagnosed and treated for endocarditis. Bold
type = different results from all 3 centers. Italics = different results from all 3
centers if borderline category included.
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asymptomatic and all the individuals in the factory were
potentially exposed. Any detectable titre could therefore
represent past infection or exposure. In addition, it is not
possible to ascertain from this study the sensitivity and
specificity of the chronic serological profile in each country
as Chronic Q fever is difficult to diagnose and requires more
detailed investigation than carried out here.
However, it is possible to compare the results and it is ap-
parent that the UK test produced the fewest negative results (11
cf 17 [Aus] cf 34 [France]), the most chronic serological profiles
(9 cf 0 cf 0) and the most ‘‘borderline’’ chronic serological
profiles (8 cf 3 cf 1).
The discrepancy in the results obtained by the different cen-
ters has clear implications for the interpretation of serological
results.
1. The indiscriminate application of cut off points or criteria
for interpretation of serological results (including the
indiscriminate use of the phase 1 IgG >800 cut off
proposed in the modified Duke criteria) is questioned.
2. Serological evaluation of treatment response using
microimmunofluorescence will vary according to the
testing center being used.
3. Sero-epidemiological studies will produce different
results according to the center in which the testing is
carried out. As the diagnosis of Q fever infection is based
primarily on serological profiles, this discrepancy
hampers our understanding of the natural history of Q
fever infection.
The differences in the results are surprising given that all 3
centers were using the same microimmunofluorescence method.
Strain differences (Table 2), growth substrate, manufacturing
technique, and use of different antigenic material are possible
explanatory factors.
This study has not provided any additional evidence on the
utility of Q fever PCR in establishing a diagnosis of chronic Q
fever endocarditis or vascular infection. While a positive PCR in
blood is undoubtedly helpful, the long-term outcome of patients
with negative PCR results and a chronic serological profile
(when tested in the UK) has not been established.
CONCLUSIONS
This study has shown that the results from Q fever micro-
immunofluorescence vary according to the center in which they
are carried out. This has implications for the interpretation of
such tests, raises questions regarding the validity of using sero-
logical criteria alone as a means of diagnosing Chronic Q fever
and affects the interpretation of epidemiological studies. We
recommend that all results are interpreted according to the
clinical picture and that particular caution is applied in the in-
terpretation of chronic serological profiles since the results from
this study show that the serological diagnosis of chronic Q fever
varies according to where the test is performed. In order to
further our understanding of Q fever infection, we propose that
an international standard of Q fever serological investigation is
developed.
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Abstract
A Spanish study has demonstrated the presence of protozoa in the sputum of respiratory patients
admitted to  hospital with acute  exacerbations  of  respiratory  disease.  These  findings  have  not
previously been replicated elsewhere in the world. Sputum was obtained from two case series of
patients;  firstly  inpatients  with an acute  exacerbations  of  respiratory  symptoms,  and the  other
consisting mainly of chronic outpatients; both at Llandough Hospital, Cardiff, South Wales. Sputum,
stained using the  Papanicolaou  method,  was  examined under  a  microscope  using previously
published criteria to determine the presence of protozoa. In the first series of ten inpatients, five
patients  (50%;  95% CI  24  –  76%) had protozoa  in their  sputum.  In the  second series  of  17
generally  less  acute  patients,  one  clearly  had protozoa and two  possibly  had protozoa  in their
sputum.  Protozoa  may  have  an  important  pathogenic  role  in  asthma  which  merits  further
examination.
Introduction
The  diagnosis  of  asthma  is  primarily  based  on  clinical  assessment  rather  than  on  definitive
diagnostic tests [1]. It can be argued that asthmatic patients may include a cluster of aetiologies
that produce a similar clinical pattern rather than a single disease process. This pilot study focuses
on one factor that may have some relevance in a proportion of respiratory patients that have a
diagnosis of asthma or COPD.
There is significant overlap in the symptoms of patients with asthma and COPD. A relevant history
of  smoking or occupational exposure,  and spirometry  can help to  differentiate between the two
conditions.  Symptomatic  improvement in response to  a trial of  beta-2 agonists  is  also a useful
indicator of asthma. The aetiological distinction between asthma and COPD is further complicated
by the fact that a proportion of patients have both conditions and there may be etiological factors
that are common to both conditions.
Asthma appears to involve a complex interaction between environmental and genetic  factors. A
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wide range of allergens have been identified, which can trigger respiratory symptoms in sensitized
individuals. Acute viral infections are also recognized triggers in both asthma and COPD, as are
exercise, hormonal changes and stress. In addition, in some individuals, asthma and COPD are
related to exposure to allergens or noxious factors that are present in the individual’s occupational
environment.
Infectious agents have also been proposed as having an etiological role in asthma. One of the
most widely recognized hypotheses for the aetiology of asthma is the hygiene hypothesis [2] which
was postulated to address the observation that children from larger families, who are presumably
exposed to  more  infectious  agents  through their  siblings,  display  less  allergic  symptoms  than
children from families with only one child. However, it is possible that infectious agents, including
protozoa are more directly implicated in etiology of acute exacerbations of asthma and COPD.
This  study is  based on previous work exploring the role of protozoa in patients  with respiratory
symptoms. A number of small published studies of Spanish patients have explored the presence of
protozoa in the sputum of  respiratory  patients  admitted to  hospital with acute  exacerbations  of
disease [3,4] or patients who were immuno-compromised [5,6]. In one study [3],  15/19 patients
(79%; 95% CI 35% – 92%) with asthma had protozoa in their sputum, as opposed to 9/78 patients
(12%; 95% CI 6% – 21%) with other respiratory  diseases, most usually  COPD. The observed
difference in prevalence (67%; 95% CI 43% - 81%) was statistically significant.
The  aim of  this  pilot  study  was  to  determine  whether  protozoa  could  be  identified in  similar
respiratory patients in the UK.
Materials and Methods
Two case series  of  patients  had sputum collected several months  apart.  One case series  was
based mainly on inpatients and the other case series was based mainly on outpatients. The first
case  series  comprised ten patients  who  were  admitted to  Llandough Hospital,  Cardiff,  South
Wales, with an acute exacerbation of respiratory symptoms. The second case series comprised 17
patients, many of whom attended a COPD patient self help group, and who were generally less
acutely ill than the patients in the first case series.
An information sheet was provided to all the patients involved in the study and written consent was
obtained.  A  sterile  sputum container  was  left  with  each  patient.  The  sputum collected  was
transferred to two microscope slides. A small area of true sputum (not saliva), about the size of a
large  lentil,  was  taken from the  expectoration using  tweezers.  The  sample  was  placed  on a
microscope  slide  (frosted  labeling  area  upwards)  and,  a  second  slide  (frosted  labeling  area
downwards) was used to make a smooth, uniform smear, gently  moving both slides in opposite
directions, and exerting slight pressure whist gently holding the frosted labeled area of the slide
between the thumb and forefinger. Both of the slides were immediately fixed using a commercially
available hair lacquer, spraying the whole surface of each slide from a distance of approximately 30
cm for a few seconds. The slides were left face up to dry to make certain that none of the material
seeped out at the edges. Every effort was made to ensure that the sample observed under the
microscope consisted of sputum and not of saliva.
The microscope slides were stained using a modified Papanicolaou method [7] and the slides were
scanned under the microscope to identify flagellated protozoa. Protozoa were differentiated from
ciliated epithelial cell remnants using the criteria in Table 1, based on previously published work
[4,3].
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Table 1: Morphological basis for distinguishing between protozoal forms and ciliocythophthoria
When in doubt about distinguishing between protozoa and epithelial cell remnants,  the following
characteristics were particularly relied on during examination under oil immersion:
Cytoplasmatic plasticity with ameboid-like forms1.
Irregular insertion of numerous flagella around all the cellular border and absence of terminal
bar
2.
Size about 12-20 microns3.
Background with red granules  (1-3  microns  in diameter),  and a  characteristic  eosinophylic
material as a cloud
4.
Quality  assurance of  the  process  involved:  clear  explanation to  patients  on how to  produce  a
good-quality sample of sputum; rapid fixing of slides; a robust protocol for labeling of slides with
unique patient identifiers; transport using approved containers for such samples; and assessment
of sputum quality under the microscope based on the presence of macrophages in the smear.
Ethical approval for the study was obtained from the South East Wales Local Research Ethics
Committee  Panel C (Ref  05/WSE03/134)  and informed consent  was  obtained in line  with the
Helsinki declaration.
Results
In the first case series, protozoa were observed in the sputum of five of the ten inpatients (50%;
95% CI 24 – 76%). All the patients in the sample had been admitted with an acute exacerbation of
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respiratory disease and were over 18 years of age. Other demographic details were not available
for this case series.
In the second case series of 17 patients, mainly made up of outpatients, one case had protozoa
and two had possible protozoa in their sputum. Some of the characteristics of this case series are
given in Table 2.
Taking both case series together six of 27 patients (22%; 95% CI 11% - 41%) with respiratory
disease had protozoal forms in their sputum.
Table 2: Characteristics of the second case series of 17 respiratory patients tested for the
presence of protozoa
An example of a protozoal form in sputum is shown in Figure 1.
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Figure 1: Example of protozoa in sputum
Discussion
This small pilot study provides some evidence that protozoa are present in a proportion of patients
in the UK who have acute exacerbations of respiratory disease. This pilot study confirms previous
observations regarding the presence of protozoa in the sputum of Spanish patients, but in case
series in patients living in a more temperate climate. The higher rate of infection in inpatients than
in  outpatients  may  indicate  that  protozoal  infection  was  in  some  way  associated with  acute
exacerbations of disease.
It is unclear whether a single species of protozoa is being observed in all patients. It is also unclear
whether  these  organisms  are  commensals  or  have  any  pathogenic  significance  whatsoever.
Although the respiratory tract has historically been considered free from micro-organisms, in the
absence of acute infection, there is some emerging evidence that organisms may be present in the
respiratory tract without having a clear pathological role.
There is relatively little published literature on protozoa in the sputum of patients with asthma or
COPD. A number of studies that have identified protozoa in the sputum of respiratory patients and
infections related to protozoa have recently been reviewed [8]. Several studies have demonstrated
chlamydia  in the  sputum of  a  proportion of  patients  with asthma  [9,10]  and a  number of  case
reports from Chinese researchers have also identified protozoal organisms in patients with asthma
[11,12].
Protozoa  are  often difficult  to  culture  and previously  reported attempts  to  culture  the protozoa
identified  in  sputum have  been  unsuccessful  [3].  Culture  of  the  protozoa  would  allow  the
examination of the effect of the protozoa on respiratory epithelial cell cultures. There is also the
potential to undertake PCR amplification of 18S rDNA to determine whether the protozoa present in
sputum is  a known species,  or is  similar to a known species.  Characterisation of the protozoa
would allow us to determine whether the same species of protozoa is  appearing in this diverse
group of patients with respiratory symptoms. These techniques would allow the development of a
rapid diagnostic technique to identify the presence of protozoa in sputum samples.
There is also a need for further work on the natural history of protozoa in the lungs, to determine
whether  the  protozoa  are  present  in patients  over  a  prolonged period of  time  or  only  appear
transiently.  The  relationship between acute  exacerbations  of  respiratory  illness,  recovery  from
illness,  and  the  presence  or  absence  of  protozoa  in  the  respiratory  tract  also  needs  to  be
determined.
If the protozoa can be cultured, their antibiotic sensitivity could be determined and a randomized
control trial could be undertaken to determine whether clearance of the protozoa in symptomatic
patients resulted in a more rapid recovery from an acute exacerbation of disease, or alternatively
whether treatment of patients with chronic respiratory disease resulted in long term improvement in
symptoms.  Successful treatment  of  a  very  small number  of  individuals  with metronidazole  has
suggested  that  this  may  be  an  appropriate  antibiotic  to  test  in  a  larger  therapeutic  trial,  in
individuals  who  have  an  acute  exacerbation  of  asthma/COPD  and  where  protozoa  can  be
demonstrated in the sputum.
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Background: Atypical infectious agents have been proposed as potential contributors to
asthma. A novel set of morphological and staining criteria permit the identification of flagel-
lated protozoa in sputum. This case-control study was designed to use this novel method
and to assess: (1) are protozoa more common in asthmatics than in non-asthmatics; (2) is
the presence of protozoa associated with the use of steroid inhalers; and (3) is the presence
of protozoa associated with living in damp housing?
Methods: Induced sputum samples were collected from asthma patients and local non-atopic,
non-smoking controls. Questionnaires assessed asthma severity and housing conditions.
Sputum was examined for flagellated protozoa using a previously described staining technique.
Results: 96 participants were recruited for this study; 54 asthma patients and 42 controls, age
range 21e62 years, 70% female participants. Limiting results to those who were clearly positive
or negative for flagellated protozoa, 66.7% (20/30) of asthmatics and 30.8% (4/13) of controls
had protozoa (pZ 0.046). Among the asthma patients, prevalence of protozoa was not signif-
icantly different between those who had (10/18), and those who had not (10/12), used steroid
inhaler in the preceding two weeks (p Z 0.11). Similarly, the prevalence of protozoa was not
significantly different between those who did (6/11) and those who did not (18/32), live in
damp homes (p Z 0.92).
Conclusions: This case-control study demonstrates an association between flagellated
protozoa in sputum and asthma. It is now necessary to confirm and characterise the protozoaHealth Sciences, St George’s University of London, Cranmer Terrace, London, SW17 0RE, UK.
0807599.
.ac.uk (H.C. van Woerden).
0 Elsevier Ltd. All rights reserved.
878 H.C. van Woerden et al.using genetic techniques based on 18S ribosomal RNA. Once tis is established it would be
worthwhile to determine if asthma symptoms improve when treated by anti-protozoal agents.
ª 2010 Elsevier Ltd. All rights reserved.Background
A wide range of aetiological factors have been suggested as
possible causes of asthma1,2 including the hygiene hypothesis3
which postulated that differential exposure to infectious
agents might have an aetiological role in asthma. Viral infec-
tions of the respiratory tract are widely accepted as an
important factor in acute exacerbations of asthma4,5 and some
authors have suggested that asthmamay even be an infectious
disease.6 There is growing interest in the potential contribu-
tion of a number of atypical infectious agents to the aetiology
of asthma, particularly Mycoplasma and Chlamydia.4,7,8
A number of case series have previously demonstrated
the presence of flagellated protozoa in the sputum of
patients with respiratory symptoms admitted to hospitals in
Spain andWales with acute exacerbations of disease9e11 and
in patients who were immuno-compromised.12,13 These
studies have demonstrated that flagellated protozoa are
present in a proportion of respiratory patients, particularly
those with asthma, when using a set of staining techniques
that have not previously been utilised in the field of sputum
cytology to identify protozoa. Another reason why flagel-
lated protozoa have not been widely recognised in sputum
samples is that flagellated protozoa are easily mistaken for
ciliated epithelial cells.14 The cyto-pathologists involved in
this study have described a set of morphological and staining
criteria to differentiate flagellated protozoa from ciliated
cell fragments.9,10
It is unclear whether the protozoa observed in the respi-
ratory case series above are more common in patients with
asthma than healthy controls; whether their presence is
related to other factors such as the use of steroid inhalers; or
whether their presence is related to living in damp home
conditions. It can be argued that steroid inhalers could
dampen the immune system and facilitate the growth of
commensal protozoa. Dampness, mould and other indoor bio-
aerosols have also been associated with a variety of respira-
tory symptoms including Building Related Illnesses, and bio-
aerosols including microbes, fungi, viruses, protozoa, pollens,
dander and mite-related debris are present in indoor air in
significant quantities.15e17 The smaller sized particles in a bio-
aerosol remain airborne for long periods of time, and also fall
within the respirable size fraction. It was therefore, consid-
ered important to consider whether living in a damp homewas
associated with the presence of protozoa in sputum.
This case-control study was designed to test three
hypotheses arising from these considerations: (1) are
protozoa more prevalent in asthmatics than in non-asth-
matics, (2) is the presence of protozoa associated with the
use of steroid inhalers, and (3) is the presence of protozoa
associated with living in damp housing?
Methods
Asthma patients and control subjects were recruited from
two GP practices in Battersea, south west London and fromWandsworth Primary Care Trust, south west London.
Control subjects were non-smokers who did not have
a history of asthma, eczema, or hay fever. For this study
the definition of asthma was: physician diagnosed asthma,
currently under active management by the patient’s GP, as
recorded in the practice’s computer records.
To recruit asthma patients, a letter was sent to all the
patients on the asthma register of both GP practices
explaining the study design and inviting them to participate.
Notices were also placed in the waiting rooms of the GP’s
surgeries inviting individuals who did not smoke and who did
not have asthma, eczema or hay fever to volunteer as
controls. Some participants were recruited by word of
mouth. Patients and control subjects were paid a small
amount in recognition of the time involved in participating in
the study. Participants were subsequently asked to complete
a questionnaire gathering demographic details, oral or
inhaled steroid use in the preceding two weeks, and asthma
symptoms in the preceding two weeks. A previously pub-
lished asthma score, AS-218 was used to assess the severity of
asthma. This score is based on four questions: Howmany days
did you cough in the past 2 weeks? How many days were you
wheezy in the past 2 weeks? Howmany dayswere you short of
breath in the past 2 weeks? How many days were you awak-
ened at night due to your asthma in the past 2 weeks? The
questions are marked on a scale of 1e4, where 1 is “Not at
all”, 2 is 1e3 days, 3 is 4e7 days and a score of 4 is 8e14 days.
The average score of the four questions forms the AS-2 score.
The presence of damp in the home was assessed using
a previously published score.19 This score incorporates four
questions: Is there any visible mould growth on your house? Is
there any odour of mould or cellar-like fusty air in your
house? Is there anymoisture stains in your house? Is there any
water/moisture damage in your house? A positive answer to
any of these questions was taken to indicate a “damp” home.
Participants then attended a clinic held at their GP
surgery where an induced sputum sample was collected. Any
individuals who had been on oral steroids in the preceding
twoweeks, or had suffered from a respiratory tract infection
in the preceding two weeks, or who had a baseline Peak
Expiratory Flow Rate (PEFR) of less than 70% their predicted
value (based on gender, height and age)were asked to return
at a later date. A standard protocol, using normal saline
(0.9%) as the nebulised solution, was used to induce sputum
production based on widely used sputum induction meth-
ods.20e23 Participants were pre-medicated with three puffs
of Salbutamol via a spacer device to reduce the risk of
inducing bronchospasm. Peak flows (best of three attempts)
were checked at 30 s, 2 min, 6 min, 10 min, 14 min, and
18 min, giving a maximum nebulisation time of 18 min.
Nebulisation was stopped after a shorter interval if an
adequate sputum sample had been produced. The procedure
was terminated if the peak flow fell by 20% of the baseline
PEFR, if the participant becamewheezy, or if the participant
wished at any point to terminate the procedure. Sputum
samples were collected in sterile petri dishes. Samples were
considered adequate when at least two or more opaque,
Figure 1 Selecting sputum, as opposed to saliva, using the
pick technique.
Association between asthma and protozoa in sputum 879muco-cellular clumps at least 1.5  3.0 mm in size had been
collected.22,24 Samples of true sputum (not saliva), were
taken from the petri dish using sterile disposable tweezers to
minimise salivary contamination of the samples using
a standard ‘pick technique’ (Fig. 1). The sputum sample was
placed on a microscope slide and, a second slide was used to
make a smooth, uniform smear, gently moving both slides in
opposite directions, without exerting undue pressure. The
two microscope slides obtained from each participant were
immediately fixed using Cytofix spray. The microscope
slides were stained using previously described techniques9
and examined for the presence of flagellated protozoa by
a cyto-pathologist using a previously described set of
morphological criteria.9,10,14 All the slides were scanned in
a systematic manner under the microscope. Slides that had
only scanty squamous cells or scantywhite cells were classed
as ‘inadequate’ as it was presumed that these slides con-
tained little true sputum. Differential cell counts were
calculated for each individual in the study based on a sample
of 100 cells. Duplicate countswere undertaken on a subset of
the samples to confirm the accuracy of the initial cell counts.
Fig. 2 provides an example of degenerative phenomena inFigure 2 Degenerative changes in ciliated bronchial cells
(Magnification  1000).ciliated bronchial cells and Fig. 3 provides an example of
protozoa in the sputum of a patient with asthma, although
not a participant in this study.
Participantswere informed if protozoawere found in their
sputum, although they were advised that the significance of
this finding was currently unknown. Any willing participants,
particularly those with protozoa, were invited to re-attend
the clinic on more than one occasion to provide an additional
induced sputum sample.
For the purposes of statistical analysis, participants who
had sputum collected on more than one occasion were
classed as “positive for protozoa” if protozoa were detec-
ted on any occasion. Participants were particularly
encouraged to return to provide another sample where the
first sample was classified as “inadequate” or “unclear”.
This was because participants’ technique improved over
time, and better quality sputum samples were often
produced at the second visit. To assess whether our colla-
tion of the positive results was reasonable, a sensitivity
analysis was undertaken using only sputum collected at the
first visit. This did not materially change the direction of
any finding, although the smaller sample size reduced the
statistical significance of the findings (data not shown).
Data were entered and analysed using SPSS 14 for
Windows. EpiInfo Version 6 was used to calculate Fisher’s
Exact Test. The study protocol was approved by Camden
and Islington community local research ethics committee
(Reference 08/H0722/540).
Results
Demographic data
A total of 96 individuals, 15 male and 39 female asthma
patients, and 14 male and 28 female controls subjects
participated in the study. There were no significant
differences between the mean age of asthma patients
(39.4 yrs; range 16e64 yrs) and the mean age of controls
(37.1 yrs; range 21e62 yrs). Amongst the asthma patients,
87% (47 individuals) were non-smokers, 7.4% (4 individuals)Figure 3 Flagellated protozoa from the sputum of an asthma
patient clearly demonstrating the presence of “capitullum”
and irregular flagella (Magnification  1000).
Table 1 Summary of the presence or absence of protozoa in study participants.
Protozoa
present
Protozoa
absent
Unclear whether
protozoa present
Inadequate
sample (saliva)
No sputum
obtained
Total
Asthma patients 20 10 3 1 20 54
Controls 4 9 2 0 27 42
Total 24 19 5 1 47 96
880 H.C. van Woerden et al.were current smokers, and 5.6% (3 individuals) were ex-
smokers. Control subjects were selected based on being
non-smokers and having a low probability of being atopic,
by using a set of screening questions to identify a history of
asthma, eczema and hay fever. None of the control
subjects had asthma, although in five cases the information
available could not fully exclude the possibility of previous
eczema or hay fever. The 96 participants made 137 visits to
the clinic and attempts to collect sputum were successful in
58.4% of attempts (80/137).
A breakdown of the results in patients and controls is
provided in Table 1. One participant withdrew from the
study, and nebulisation was stopped in one patient who
became wheezy. There was one inadequate sample, where
only saliva rather than muco-cellular content was present
on the microscope slides. In five cases, the cyto-pathologist
was uncertain over the presence or absence of protozoa in
the sample provided. Forty-six participants did not produce
any sputum. Protozoa were identified in 20 asthma patients
and 4 control subjects.
No statistically significant relationship was observed
between the presence or absence of protozoa and the
proportion of eosinophils, monocytes/macropages or
neutrophils observed in sputum smears when the differ-
ences were assessed using the ManneWhitney test.
Were protozoa more common in asthmatics than in
non-asthmatics?
The prevalence of protozoa in asthma patients was 66.7%
(20/30) and in controls, it was 30.8% (4/13). Fisher’s Exact
Test comparing the proportion of asthma patients and
control subjects in which protozoa were clearly ‘present’ or
‘absent’ gave a p value of 0.046, relative risk of 1.58 (95% CI
1.00e2.51). The data supports the hypothesis that protozoa
are more prevalent in patients diagnosed with asthma than
in comparable controls.Table 2 Comparison of the presence or absence of
protozoa against the use of a steroid inhaler in the
preceding two weeks, among 30 asthma patients.
Protozoa in sputum Total
Yes No
Have you taken a
steroid/preventative
inhaler in the last
2 weeks?
Yes 10 8 18
No 10 2 12
Total 20 10 30Was the presence of protozoa associated with the
use of steroid inhalers?
To determine whether the presence of protozoa was asso-
ciated with the use of steroid inhalers, we compared the
proportion of asthma patients with and without protozoa in
their sputum against self-reported use of a steroid inhaler in
the preceding two weeks. The prevalence of protozoa in the
sputum of asthma patients who had not used a steroid
inhaler in the preceding two weeks (83%, 10/12), was higher
than the prevalence in those who had used a steroid inhaler
in the preceding two weeks (55.5%, 10/18). However, this
difference was not statistically significant (chi-square 2.50,
p Z 0.114). See Table 2. These findings do not support the
hypothesis that an increased prevalence of protozoa in
sputum is associated with recent use of steroid inhalers.
Was the presence of protozoa associated with living
in a damp home?
The presence or absence of protozoa in sputum was
compared against the presence of damp in the home. The
score was dichotomised (‘no evidence of damp’ against ‘any
evidence of damp’) as it had been in the paper from which
this set of questions were taken. See Table 3. Analysis was
limited to those who had clear positive or negative result for
protozoa in their sputum. The prevalence of protozoa was
not significantly different between those who did (54.5%, 6/
11) and thosewho did not (56.3%, 18/32), live in damp homes
(p Z 0.92). In summary, the data do not support the
hypothesis that an increased prevalence of protozoa in
sputum is associated with living in damp housing.
Over what duration did protozoa persist in the
sputum of an individual?
Some information was obtained on the duration over which
protozoa persist in the sputum of an individual. Table 4
summarises the information on 12 participants who hadTable 3 Comparison of the presence or absence of
protozoa against evidence of damp/mouldy in the home.
Protozoa in sputum Total
Yes No
No evidence
of damp/mould
18 14 32
Evidence
of damp/mould
6 5 11
Total 24 19 43
Table 4 Observed duration of the presence of protozoa in
participants.
Patient or Control First visit Later visit Interval (days)
Asthma patient Protozoa Protozoa 103
Asthma patient Protozoa Protozoa 88
Asthma patient Protozoa Protozoa 80
Asthma patient Protozoa Protozoa 46
Asthma patient Protozoa Protozoa 37
Asthma patient Protozoa Protozoa 17
Asthma patient Protozoa Protozoa 14
Asthma patient Protozoa Protozoa 8
Asthma patient Protozoa Protozoa 2
Asthma patient Protozoa Protozoa 2
Asthma patient Protozoa Protozoa 2
Control Protozoa Protozoa 18
Association between asthma and protozoa in sputum 881sputum samples taken on two separate visits to the clinic.
The mean interval between the two visits was 34.75 days
(range 2e103 days).
Three patients had protozoa in their sputum at one visit
but not at the other visit. The change in PEFR before
induced sputum was collected, comparing the two visits,
was around 10 l/min in all three cases, with the higher PEFR
readings occurring on the occasions when protozoa were
identified. This sample size is too small to determine
whether asthma symptoms were significantly different but
merits further investigation in a larger sample.
Do symptoms and PEFR differ between asthma
patients with and without protozoa in their
sputum?
To assess whether protozoa were more likely to be present in
the milder or more severely affected asthma patients, the
distribution of the AS-2 asthma scores in those asthma
patients who had, and thosewhodid not have, protozoawere
compared. Themedian AS-2 score in those with protozoawas
1.25 and in those without protozoa the median score was
1.75. The ManneWhitney U statistic was 59.5, p Z 0.068.
Although the asthma patients with protozoa in their sputum
generally had milder asthma than those who did not have
protozoa, the difference was not statistically significant.
The relationship between peak flow and the presence or
absence of protozoa in the sputum of asthma patients was
assessed using the ManneWhitney test, with equal vari-
ances not assumed. There was no relationship between
peak flow (best of three blows at the start of the proce-
dure) and the presence of protozoa (p Z 0.252). Similarly,
there was no relationship between the presence or absence
of protozoa and the lowest peak flow recorded during the
sputum induction procedure (p Z 0.14).
Discussion
This case-control study demonstrates an association between
the presence of protozoa in induced sputum samples and
a previous GP diagnosis of asthma. No association was found
between the presence of protozoa and the use of steroid
inhalersor thepresenceofprotozoaand living indamphousing.The prevalence of protozoa in asthma patients (66.7%)
was broadly similar to that seen in a previous Spanish
study.9 The Spanish study also examined patients with
other respiratory diseases, mostly COPD, but did not study
health controls.
Asthma may represent a cluster of conditions with
similar symptoms2,25 and it is possible to speculate that the
presence of protozoa represents a relatively mild infection
which produces asthma like symptoms. The relatively high
proportion of non-asthmatic individuals who had protozoa
in their sputum also suggests that in many individuals these
protozoal organisms do not have a pathogenic role.
However, a number of recent papers have demonstrated
that a range of organisms are present in the healthy lung
but are more common in COPD or asthma.26,27 There is
clearly growing interest in the role of infective organisms in
asthma, but their role and significance is still unclear.
However, it is possible to speculate that the protease
enzymes that protozoa produce could act in the same way
as Der P1 to breakdown the tight junctions between
epithelial cells, increase the shedding of epithelial cells in
the respiratory tract, and facilitate the penetration of
allergens into local tissues. It is also possible to speculate
that degenerative remnants from the cytoplasm or cell
membrane from dead protozoa could act as an ‘adjuvant’,
magnifying the immune response to concomitantly pre-
sented allergens.28e30 If asthma is viewed as a symptom
cluster caused by range of underlying aetiologies, respira-
tory tract infection with protozoa could be a contributory
factor in a subset of asthma patients.
Comparing the demographic characteristics of patients
and controls does not suggest that our approach to the
recruitment of cases and controls has introduced significant
bias. In addition, the cyto-pathologist examining the
sputum samples was blinded as to whether each sample
came from an asthma patient or a control subject. Analysis
of data was also undertaken independent of data
collection.
The main weakness of the study is its relatively small
size. The study would also have been strengthened by
further classification of asthma, including a more
detailed assessment as to whether patients had intrinsic
or extrinsic asthma and an assessment of other end points
such as exhaled nitric oxide levels. The study could have
been strengthened by having the sputum slides examined
by two independent cyto-pathologists, as the character-
istics used to define the presence or absence of protozoa,
have not been externally validated by an independent
laboratory. Consequently, we currently have no estimate
of the false positive or false negative rate for the
assessment of the microscope slides by our cyto-
pathologist.
We chose to use normal saline in the ultrasonic nebuliser
as it tastes more pleasant and is less likely to trigger
bronchospasm.22,24 This may have contributed to the rela-
tively low proportion of control patients in whom sputum
was obtained (35.7%, 15/42). The proportion of participants
who produced sputum might have been higher had we had
used hypertonic saline. If the prevalence of protozoa in the
sputum of those control participants from whom sputum
was not obtained was zero, then the incidence of protozoa
could have been as low as 9.5% (4/42). It is possible to
Appendix 1. Instructions for obtaining sputum
smears
1. The sputum should be deposited in a sterile container.
2. A small area of true sputum (not saliva), about the size
of a large lentil, should be taken from the expectora-
tion using tweezers and scissors.
Step 1
Step 2
882 H.C. van Woerden et al.speculate that the control subjects who did not produce
any sputum after nebulisation may have been less atopic
and had lower bronchial reactivity. Similarly, further
testing (for example, by skin prick tests) of the four
controls that had protozoa to detect any underlying atopic
tendency would have been helpful.
It is possible for induced sputum samples to be
contaminated by oral microbiota. However, a study
comparing the bacteria present in oral, induced sputum and
bronchial lavage samples taken from the same individuals
has provided some reassurance that this is not a major
issue27 The ‘pick technique’ that we have used should also
have ensured that most of the material smeared across
a slide comes from the inside of the gelatinous sputum
globules that were individually picked up and placed on
microscope slides. Although the surface of such globules
would have some contact with saliva, this would only form
a small proportion of each sputum sample as each sample
was smeared on a microscope slide. There is evidence that
protozoa live in the biofilms that form dental plaque.31e33
As the oral and respiratory mucosa form one continuous
surface, it is clearly possible that there could be a link
between oral and respiratory tract protozoa.
Conclusions
This case-control study supports the hypothesis that the
presence of protozoa in sputum is statistically associ-
ated with a clinical diagnosis of asthma. It provides
sufficient evidence to suggest that this hypothesis
requires further exploration to determine whether these
organisms are playing any primary or secondary patho-
genic role, or whether their presence is merely an
incidental finding.
It would be helpful if the organisms could be charac-
terised using molecular techniques, for example, based on
the characterisation of 18s RNA, as at present the species of
protozoa observed is unknown and we cannot determine
whether the same species of organism is present in
different samples. Once this is established, a trial of anti-
protozoal agents would also be worthwhile, to determine
whether asthma symptoms improve when these protozoa
are killed by an anti-protozoal agent. Similarly, trials of
antibiotics have been used to assess the impact of the
treatment of Chlamydia infection in patients with
asthma.34
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3. Place the sample on a slide (frosted edge upwards) and,
with a second slide (frosted edge downwards) make
a smooth, uniform smear. It is not appropriate to crush
the sample, but rather to move both slides in opposite
directions, exerting slight pressure. To facilitate this
operation, take the frosted edge of each slide between
thumb and forefinger.Acknowledgements
We are grateful to the two GP practices that assisted us in
this study: Battersea Fields Practice, and Lavender HillGroup Practice, and also to Wandsworth PCT who funded
the study.
Step 3
Step 4
4. Immediately fix the smears on both slides with
commercially available hair lacquer, spraying the whole
surface from a distance of approximately 30 cm. Make
sure to spray the surface of the slides where the smears
are (that corresponding to the frosted area of the edges).
Before introducing the fixed slides into their containers
for dispatch, leave them face up for a while until certain
that none of the material seeps out at the sides.
Step 5
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Clinical and Immunological
Characteristics Associated With
the Presence of Protozoa in
Sputum Smears
Rafael Martı´nez-Giro´n, M.D., Ph.D.,1* and
Hugo Cornelis van Woerden, M.B.Ch.B., M.P.H., F.F.P.H., M.R.C.G.P.2
The objective of this study is to assess the relationship between
protozoa in spontaneously expectorated sputum samples and a
range of clinical and immunological variables. Clinical details
including age, gender, smoking status, and use of oral or
inhaled steroids were recorded for a cohort of 199 patients
whose spontaneously expectorated sputum samples were submit-
ted to a Cytology Laboratory in Spain between January 2005
and December 2006. Slides were scanned for protozoa under
light microscopy and scanned for monocytes/small macrophages
highlighted by immunocytochemistry (CD68 monoclonal anti-
body). One hundred ninety-one patients provided adequate spu-
tum samples, of whom 70 had protozoa in their sputum. There
was a strong relationship between the presence of protozoa and
monocytes/small macrophages identiﬁed under light microscopy
(P < 0.001). A binary logistic regression model also indicated a
relationship between protozoa and both smoking status and ste-
roid use. The diagnoses in those with protozoa included infec-
tion (including tuberculosis), chronic obstructive pulmonary dis-
ease (COPD), lung ﬁbrosis, asthma, chronic liver disease, immu-
nosuppression, cancer, pancreatic or renal disease, heart
failure, and AIDS. The identiﬁed association between protozoa
and monocytes/small macrophages in sputum suggests an
immune response and warrants further investigation to clarify
whether or not these organisms have any pathological signiﬁ-
cance in this wide range of conditions. Diagn. Cytopathol.
2011;00:000–000. ' 2011 Wiley-Liss, Inc.
Key Words: monocytes/small macrophages; protozoa; sputum
smears; respiratory disease
Microscopy of spontaneously expectorated sputum pro-
vides a simple, noninvasive technique for identifying ma-
lignant and inﬂammatory cells in the respiratory tract.1–3
The pattern of inﬂammatory cells present in a sputum
sample can predict response to treatment. Thus, the pres-
ence of eosinophils in sputum predicts corticosteroid
response in some asthma patients.4 This suggests that the
relationship between other inﬂammatory cells and respira-
tory disease may also be worth investigating.
Monocytes and small sputum macrophages are associ-
ated with a range of respiratory diseases.5,6 As the precur-
sors of alveolar macrophages, monocytes are recruited into
the lungs7 and contribute to the respiratory system’s
defence against a range of pathogens.8 The presence of
monocytes/small macrophages can be readily assessed on
the basis of morphological features and antibody staining.9
In a number of previous reports, we have identiﬁed
multiﬂagellated protozoa in sputum from patients with a
range of disorders.10–14 During those investigations, an
anecdotal observation was made that monocytes/small
macrophages were more commonly present in samples
that contained protozoa. The purpose of this study was,
therefore, ﬁrst to quantify the relationship between the
presence of protozoa and monocytes/small macrophages
in sputum and second to assess the relationship between
the presence of protozoa and range of other available clin-
ical variables.
Materials and Methods
Information was prospectively recorded on a consecutive
cohort of patients whose spontaneously expectorated spu-
tum samples were submitted to the Cytology Laboratory,
in the Central University Hospital, Asturias, Oviedo,
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Spain between January 2005 and December 2006. Clinical
details including age, gender, smoking status, and use of
oral or inhaled steroids was recorded for each patient.
Sputum samples were collected over a standard 3-day pe-
riod,15 smeared onto two glass slides using a ‘‘pick-and-
smear’’ technique, ﬁxed for 30 minutes in 96% ethanol,
and stained by the Papanicolaou method. Inadequate sam-
ples, consisting primarily of saliva, were excluded from
further analysis.
The presence of monocytes/small macrophages in a
smear (Fig. 1) was conﬁrmed based on the presence of
standard morphological features under light microscopy
including:
 cellular diameter of about 12–14 lm;
 characteristic nucleus with a bean-like appearance;
 scanty cytoplasm;
 low nuclear/cytoplasm ratio; and
 positive immunocytochemistry using a commercially
available antibody anti-CD68 (1:50 dilution, Dako
EnVisionTM, Denmark).
The variable depth and quantity of mucus on the slides
means that counting of the monocytes/small macrophages
would probably not have provided counts that could be
reliably compared. Instead, monocytes/small macrophages
were deemed to be ‘‘present’’ if a minimum of two areas
were identiﬁed on a slide where at least 10 monocytes/
small macrophages were present.
Protozoa were identiﬁed using previously described
criteria.15 In summary, this involved scanning of sputum
slides under light microscopy for 10–20 minutes using
the Papanicolaou stain and identifying and distinguish-
ing multiﬂagellated protozoa (Figs. 2A and B) from
ciliated epithelial fragments or other cellular debris
(Fig. 3). The ﬁrst six criteria in Table I were routinely
used to distinguish protozoa from ciliated epithelial
cells or cell fragments. The additional criteria in the ta-
ble were occasionally used to conﬁrm the presence of
protozoa. A monoclonal antibody to cytokeratin (CAM
5.2) can also be used to stain ciliated epithelial cells or
cell fragments and thus distinguish them from proto-
zoa16 (Fig. 4).
The v2 test was used to assess the relationship between
the presence of protozoa and monocytes. A binary logistic
regression model (backward stepwise—likelihood ratio)
was run in SPSS 14.0 (Chicago, IL) to examine whether
the available clinical variables predicted the presence of
protozoa. A similar model was run to assess the relation-
ship between the presence of monocytes/small macro-
Fig. 1. Clusters of monocytes/small macrophages in a sputum smear
(Papanicolaou, 3400). [Color ﬁgure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
Fig. 2. A and B: Multiﬂagellated protozoa in a sputum smears. Note the
distinctive ﬂagellar arrangement around the irregular cytoplasmic outline
(Papanicolaou, 31,000. Scale bar ¼ 10 lm). [Color ﬁgure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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phages in our sputum samples and available clinical varia-
bles: age, gender, smoking status (nonsmoker, ex-smoker,
and current smoker), and steroid use (oral or inhaled).
The data presented in this article were collected as part
of the routine work of a laboratory. Formal ethical ap-
proval was, therefore, not obtained. The study was under-
taken in full compliance with the principles laid out in
the Declaration of Helsinki.
Results
A consecutive series of 199 patients with respiratory dis-
ease each provided sputum samples. Eight patients (seven
men and one women, aged 47–86 years) were excluded
from the study as their samples were deemed ‘‘inad-
equate.’’ Data on smoking status were missing for 22
(11.5%) cases, but information on all the other variables
was complete. The mean age in the study was 66.9 years
(SD 14.6, range 28–90 years). The cohort consisted of
167 men (87.4%) and 24 women (12.6%).
Summary diagnostic information for the 70 patients
who had protozoa in their sputum is shown in Table II.
Four patients with cancer, or possible cancer, also had
COPD. ‘‘Query cancer’’ was the commonest provisional
diagnosis, present in 24/70 (34%) patients with protozoa.
Unfortunately, similar information on clinical diagnosis
was not collected from those individuals in the cohort
who did not have protozoa in their sputum.
As shown in Table III, there was a strong relationship
between protozoa and monocytes/small macrophages (v2
65.2, P > 0.001).
A binary logistic regression model to predict the
presence/absence of protozoa was produced using the fol-
lowing clinical parameters: age, gender, smoking status
(nonsmoker, ex-smoker, and current smoker), and steroid
Fig. 3. Ciliated epithelial fragment in a sputum smear (Papanicolaou,
31,000). [Color ﬁgure can be viewed in the online issue, which is avail-
able at wileyonlinelibrary.com.]
Table I. Morphological Basis for Distinguishing Between Protozoal Forms and Ciliocytophthoria
Characteristic Protozoal forms Ciliocytophthoria (ciliated epithelial remnants)
Red granules Numerous 3–8 lm; may be extracellular Few, very small (1–2 lm), intracellular
Nuclei Occasionally absent; if present perinuclear clear halo,
perinuclear corpuscles, and prominent central
karyosome
Usually absent; if present no perinuclear clear halo,
perinuclear corpuscles, with tendency to pyknosis
Cytoplasm Friable with certain plasticity; spindle or oval shape;
occasional presence of cytoplasmic vacuoles
Round or columnar shape with ﬁne granularity
Cilia or ﬂagella Wavy, not combed; different lengths Cilia alone one edge; straight, combed and the same
length; discernable terminal bar
Cellular variability Marked Little variability
Papanicolaou stain Eosinophilic Amphophilic, eosinophilic, or basophilic
Under ultraviolet light Positive autoﬂuorescence of all forms No ﬂuorescence
Heindenhain’s iron haematoxylin
stain
Positive in nuclei and internal structures Negative
Acridine orange stain Positive Negative
Wheatley’s Trichome stain Positive, magenta with granularity and red nuclei Greenish cytoplasm
Motility in wet mounts of fresh
sputum samples (<1 hour)
Wavy shaft, nonsynchronized movement Straight, short, metachronal rhythm
Fig. 4. Sputum smear. Bronchial epithelial cells positive for CAM 5.2
immunostaining (31,000). [Color ﬁgure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
PROTOZOA IN SPUTUM SMEARS
Diagnostic Cytopathology, Vol 00, No 00 3
Diagnostic Cytopathology DOI 10.1002/dc
use (oral or inhaled). The Nagelkerke R2 for the model
was 0.073, indicating that only 7.3% of the variance in
the presence/absence of protozoa was explained by the
covariates in the model (see Table IV). Based on the clas-
siﬁcation table (not shown), this model would correctly
predict 96.7% of those without protozoa but only 11.4%
of those with protozoa. When a variable for the presence/
absence of monocytes/small macrophages was added into
the model all the other variables dropped out (see
Table V). The presence of monocytes/small macrophages
explained 40.5% of the variance and correctly predicted
84.3% of cases where protozoa were absent and 74.3% of
cases where protozoa were present. The presence of
monocytes/small macrophages in sputum samples was
therefore a better predictor of the presence of protozoa
than the available clinical variables.
A similar binary logistic regression model to predict
the presence of monocytes/small macrophages, based on
available clinical parameters, showed statistically signiﬁ-
cant relationships with age, smoking status, and steroid
use, although the model only explained 13.4% of the
variance.
Discussion
This study has demonstrated a signiﬁcant relationship
between the presence of monocytes/small macrophages
and the presence of multiﬂagellated protozoa (P <
0.001). Relationships between protozoa and smoking, and
protozoa and oral steroid use were also demonstrated.
These ﬁndings are signiﬁcant in the light of a growing
body of evidence for the presence of multiﬂagellated pro-
tozoa, in both sputum and nasal extrusions from patients
suffering bronchial asthma and allergic rhinitis.17–19 Our
ﬁndings are also consistent with a number of reports indi-
cating that protozoa lead to the recruitment of monocytes
as part of the host’s immune response to infection.20–23
A relationship between smoking and the activation/stim-
ulation of human monocytes is widely recognized.24–27
This relationship was also observed in this study.
The release of monocytes by bone marrow is associated
with air pollution28 and future studies should consider the
extent to which the patients with protozoa and monocytes/
small macrophages have been exposed to air pollution.
The study has a number of potential weaknesses. The
cytologist who examined the microscope slides was not
blinded in any way and was aware of the underlying hy-
pothesis. This could have introduced some bias by inadver-
tently increasing the scrutiny for protozoa in samples that
had high numbers of monocytes/small macrophages.
Ideally, all the microscope slides should have been
assessed for protozoa and monocytes/small macrophages
by two independent observers who were blinded to each
other’s analysis. No gold standard currently exists against
which to assess the presence or absence of protozoa.
Attempts at culturing the organisms have been unsuccessful
Table II. Relationship Between Provisional Diagnosis and the Presence
or Absence of Monocytes/Small Macrophages in 70 Patients with
Protozoa in their Sputum
Main diagnosis
No
monocytes/
small
macrophages
present
Monocytes/
small
macrophages
presenta Total
AIDS 2 2 4
Asthma 1 1 2
Cancer or possible cancer
being considered
4 20 24
COPD 2 6 8
Heart failure 0 3 3
Immunosuppression 0 1 1
Infection 4 6 10
Liver, pancreatic or renal
disease
1 3 4
Lung ﬁbrosis 0 2 2
Other 2 3 5
Tuberculosis 2 5 7
Total 18 52 70
aAt least two groups of at least 10 monocytes/macrophages present
Table III. Relationship Between the Presence of Monocytes/small
Macrophages and Protozoa in Sputum Samples of 191 Respiratory
Patients
Monocytes/small macrophages
TotalNo Yes
Protozoa
No 52 18 70
Yes 19 102 121
Total 71 120 191
Table IV. Coefﬁcients for Binary Logistic Regression Model
Predicting the Presence of Protozoa in Sputum Smears
B S.E. Wald df Sig. Exp(B)
Steroids 5.503 2 0.064
Steroids (none)a 1.320 0.641 4.239 1 0.040 0.267
Steroids (inhaled)a 1.980 0.897 4.867 1 0.027 0.138
Known nonsmoker 0.620 0.312 3.959 1 0.047 1.859
Constant 0.451 .629 0.514 1 0.473 1.570
Exp(B) is the predicted change in odds for a unit increase in the covariate.
aCompared to those on oral steroids.
Table V. Binary Logistic Regression Model (When Monocytes/Small
Macrophages Covariate was Added) Predicting the Presence of Protozoa
in Sputum Smears
B S.E. Wald df Sig. Exp(B)
Monocytes/small
macrophages
2.741 0.370 54.768 1 <0.001 0.064
Constant 1.007 0.268 14.106 1 <0.001 2.737
Variables entered: monocytes/small macrophages, age, sex, inhaled corti-
costeroids, oral steroids, and smoking status.
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(unpublished data), but nonculture methods may be devel-
oped in the future to address this issue.
The cohort of patients in this study was somewhat
atypical in that it is primarily male. However, a retro-
spective review of 25 more recent cases where sputum
samples were submitted to our laboratory for cytology,
and where protozoa and monocytes/small macrophages
were not identiﬁed, indicated that a similar percentage
were male, 20/25 (80%). The preponderance of samples
from men in this laboratory may in part be due to the
high smoking rate in men in Spain, and perhaps due to
a tendency for clinicians to request sputum cytology
more often in men, as lung cancer is relatively com-
mon in Spanish men. A weakness of this study is the
absence of diagnostic information in the individuals in
the cohort who did not have protozoa in their sputum.
Future studies should collect greater clinical detail
including information on fever, respiratory symptoms,
radiographic and laboratory abnormalities, any treat-
ments and response.
The diagnoses summarized in this study were also
provided on the laboratory request form, rather than rep-
resenting discharge diagnosis and therefore need to be
interpreted with caution.
A case–control study on an association between proto-
zoa and asthma has been reported,29 and it is possible to
speculate that some of the 12 patients recorded as taking
oral steroids may have had acute exacerbations of asthma,
although this was not recorded on their laboratory request
form.
Although the protozoa we have observed may simply
be commensal organisms, our tentative ﬁnding of an asso-
ciation with an inﬂammatory response by monocytes/
small macrophages leads us to believe that, although this
line of research does not have immediate clinical applica-
tion, the role of protozoa in respiratory disease does war-
rant further investigation. A randomized controlled trial
demonstrating an improvement in symptoms and a fall in
the number of monocytes/small macrophages after eradi-
cation of the protozoa by an appropriate antibiotic would
strengthen the hypothesis that these protozoa are of patho-
logical signiﬁcance.
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Could inhaled mite faeces introduce pathogens to the lungs?Mites are small arthropods to which we are regularly
exposed. They are commonly present in bedrooms and living
rooms (house dust mites), kitchens (storage mites) and green-
houses (predatory mites). Several species including Dermato-
phagoides, Blomia, Lepidoglyphus, Tyrophagus, Tetranychus
have strong associations with allergic and occupational
diseases such as rhino-sinusitis, conjunctivitis, bronchial
asthma and atopic dermatitis.
House dust mites are sources of multiple potent allergens in
the indoor environment, and although many aspects of its
biology are not yet understood [1e3], it is widely accepted
that inhalation of mite antigens such as Der P1, found in
dust mite faeces, contributes to the aetiology of asthma.
However, mites may play a wider role in the pathogenesis of
human disease.
The presence of microbes in and on house dust mites has
been described in a number of papers. One paper identified
bacterial sources of endotoxin in mite extracts and provided
evidence that house dust mites contain Bartonella and other
Gram-negative species. DNA sequence analysis has also
shown the widespread presence of Bartonella species and
uncharacterized a-proteobacteria, in both Dermatophagoides
farinae and Dermatophagoides pteronyssinus [4]. Another
paper, examining intestinal extracts from house dust mites,
has demonstrated the existence of flagellated protozoal forms
inside dust mites [5].
Other arthropods, such as termites and cockroaches, have
also been shown to contain flagellated and ciliated protozoa
in their hindgut, where they establish a symbiotic relationship
and are necessary to the regulation of digestive processes [6]
and metabolic activities [7]. Moreover, ectosymbiont bacteria
are attached to the surface of these protozoa providing them
with some motility [8].
These observations may be of pathogenic significance in
the human respiratory tract. Infected sputum samples indicate
the entry of bacteria into the lower respiratory tract of patients
with chronic respiratory diseases, where the release of
antigens, including endotoxin, produces potent inflammatory
effects that are well described [9]. Some evidence on the path-
ogenic effects of Bartonella in human lungs has been reported
[10,11]. Uncommon flagellated protozoa have also been found
in the respiratory tract of patients suffering from respiratory
disease [12e14]. Similarly, in a small unpublished case series1286-4579/$ - see front matter  2008 Elsevier Masson SAS. All rights reserved.
doi:10.1016/j.micinf.2007.12.017of ten patients in South Wales, UK, with respiratory disease,
five patients had evidence of protozoa in their sputum.
The potential for synergistic, concurrent exposure to aller-
genic epitopes from different sources, including organisms,
has long been postulated as associated with asthma [15] and
increasing evidence is emerging for this. For example, there
is evidence that epitopes from helminths modulate allergic
processes [16,17].
Protozoal lipopolysaccharide might also act as an adjuvant.
Intranasal sensitization to ovalbumin has been shown to
develop because of contaminating low levels of endotoxin
suggesting that allergic sensitization may develop when
aeroallergens are admixed with microbial products that act
as adjuvants by activating toll-like receptors [18,19].
Inhalation of mite faeces containing Der P1 and protozoa is
feasible. The aerodynamics of Der P1 inhalation have been
assessed, both by measurement of indoor air and at the en-
trance to the nose. Der P1 has been shown to be present, at-
tached to a range of particles of different sizes, including
mite faeces. These particles are of a size that can be inhaled
deep into the lungs [20].
Our conclusion is not that protozoal infection itself is the
cause of asthma, but that the presence of flagellated protozoa
together with Der P1 may play a synergistic role or a modulat-
ing role in acute exacerbations of respiratory disease and that
further investigation is needed to explore whether there is
a clinically significant relationship between the presence of
flagellated protozoa and mite faeces Der P1 in the respiratory
tract. The epidemiology (frequency, duration, and associated
characteristics) of respiratory patients who have flagellated
protozoa in their sputum needs to be further investigated.
There is also a need to see whether eradication of any protozoa
present aids the resolution of respiratory symptoms or reduces
recurrent exacerbations of disease. DNA sequencing to
characterise the flagellated protozoa seen in microscopy of
the sputum of patients with respiratory disease is also needed.References
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Is the Dust Mite Allergen Der p1 Protozoal in Origin?
To the Editor:
The major allergen in house dust mites faeces, Der p1, is
believed to have a role in digestion of the mite’s main
food supply (human epithelium). We postulate that the
digestion of human epithelial scales by dust mites may
rely on a symbiotic relationship between protozoa and
mites, whereby the Der p1 required for mite digestion is
produced by protozoa or other intestinal commensals
rather than being of mite origin.
Der p1, a cysteine protease [1], affects matrix remodel-
ling and immuno-regulation [2]. It is a potent inducer of
proinflammatory cytokines, disrupts intercellular tight
junctions and facilitates the transfer of allergens across
the respiratory epithelial barrier [3].
There are important protozoal parallels. In parasitic
organisms, including protozoa, cysteine proteases play
important roles in pathogenic mechanisms including:
cell invasion, immunoevasion, encystment, etc. Flagel-
lated protozoa, including Trichomonas vaginalis and
Giardia lamblia, display these phenomena when parasit-
izing human mucosal cavities. Cysteine proteases have
been implicated as virulence factors utilized by T. vagi-
nalis, including cytototoxicity by extracellular matrix
proteins degradation [4], epithelial cell detachment and
apoptosis [5]. G. lamblia cysteine proteases damage
mucosa in giardiasis [6] and may increase antigen pene-
tration [7].
The Der p1 gene, also called Peptidase 1 (mite), con-
tains two active enzymes, a cysteine protease inhibitor
and a C1A cysteine peptidase. Der p1’s cysteine pepti-
dase falls within the clan CA, family C1, sub-family
C1A, which includes around 1300 sequenced enzymes
(http://merops.sanger.ac.uk/cgi-bin/make_frame_file?id=c1a;
action=tree). The C1A subfamily includes papin and
cathepsin like enzymes that are distributed widely across
many life forms including plants, nematodes, viruses,
fungi, protozoa and mammals. The difference in protein
sequence between different protozoal C1A enzymes,
using tools such as BLAST, is not greater than the dif-
ference between Peptidase 1 and, for example, a C1A
enzyme found in Tetrahymena thermophilia. This moder-
ately high level of sequence homology indicates that a
protozoal origin for Der p1 cannot be excluded,
although the sequence is not identical to that of any
know protozoa.
The studies that identified the Der p1 protein struc-
ture ⁄gene sequence used mite faeces or crushed samples
of whole mites as their starting point [8]. They did not
distinguish between gut contents and mite tissue and
cannot therefore exclude a protozoal origin for Der p1. In
contrast, Der p5 has been identified in secretory granules
of the midgut of epithelial cells of house dust mites indi-
cating that it is of mite origin [9].
Protozoal forms have been found in intestinal
extracts of dust mites [10]. Multiflagellated protozoa
have also been demonstrated in the sputum of a propor-
tion of asthmatics and we have previously postulated
that the inhalation of mite faeces could introduce proto-
zoa to the lungs.
It is conceivable, therefore, that Derp1 could be of
protozoal, rather than of mite origin, as is currently
assumed. This question is important because if it is
found that Der p1 has a protozoal origin, then a number
of existing anti-protozoal chemotherapeutic agents could
be explored as treatments for Der p1 related allergic
conditions.
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Disruption of Airway Epithelium in Asthma
Pathogenesis: Are Protozoa Responsible?
To the Editor:
In a recent paper published in this journal by Holgate and
colleagues (1), the authors state that asthma is primarily a defect
of epithelial barrier function, which allows greater access for
environmental allergens, toxicants, and microbiota to infiltrate
airway tissues. The innate immune response to viral infection,
particularly with human rhinoviruses, has been proposed as the
trigger for subsequent breakdown of the epithelial barrier. How-
ever, an alternative hypothesis is that secondary infection by
other organisms plays a role (2).
In a different context, in vitro analysis has demonstrated that
the flagellated protozoa Trichomonas vaginalis disrupts urogen-
ital epithelial monolayers, causing epithelial damage, and may
predispose to secondary HIV viral infection (3). In a respiratory
context, the identification of multiflagellated protozoa in the
sputum of patients with asthma and immune-depressed patients
has been reported (4), and it has been hypothesized that the source
of these protozoa may be the inhaled fecal pellets of dust mites (5).
A marked increase in the shedding of bronchial epithelial
cells is found on examination of sputum from patients with
asthma, signaling that the epithelial barrier of the airways is
damaged. We have suggested that proteolytic enzymes, secreted
by inhaled protozoa, could break the bonds between bronchial
epithelial cells, accelerating cellular sloughing, and compromis-
ing the effectiveness of the airway epithelium as a barrier (6).
Thus, viral respiratory infection could facilitate opportunistic
overgrowth of normally nonpathogenic protozoa, leading to
a cycle of increasing damage to airways and increased bronchial
hyperresponsiveness.
In conclusion, we agree with the assertion by Holgate and
colleagues that the integrity of respiratory epithelium is crucial
to both the origin and progression of asthma, as well as playing
a key role in asthma exacerbations. Further studies are needed
to determine whether interplay exists between viral infections
and the opportunistic overgrowth of other microbiota, including
protozoa, which could play a role in disrupting airway epithe-
lium and contribute to the pathogenesis of asthma.
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From the Author:
I was most interested to read the letter from Dr. Rafael
Martı´nez-Giro´n regarding the possibility that an interplay may
exist between viral infections and the opportunistic overgrowth
of other microbiota, including protozoa, that could contribute to
disrupting airway epithelium by breaking tight junctions through
the release of proteolytic enzymes, thereby contributing to the
pathogenesis of asthma. This is a possibility.
Indeed, there is increasing evidence that in addition to
innately unstable epithelial tight junctions in asthma, there are
a wide variety of environmental factors that possess proteolytic
activity and capable of cleaving tight junction proteins. These
include dust mite, pollen, fungal and cockroach allergens, and
occupational exposures (e.g., proteolytic enzymes in washing
powders) (1–5). There is also mounting evidence that this
epithelial perturbation serves as a danger signal in activating
and directing mucosal dendritic cell differentiation and activa-
tion (6, 7). Together, these interacting factors could be consid-
ered as part of the altered innate immune response of asthma as
well as being involved in tissue injury and repair.
In general, viruses and other microbial interactions are assum-
ing greater importance not only in the causation of exacerbations,
but also in the origins and progression of certain types of asthma
(8). There is clearly a need for further research in this field.
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